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Abstract 
In molecular diagnostics, the polymerase chain reaction (PCR) is used to amplify small 
amounts of nucleic acids found in patient samples, allowing for detection of diseases within 
hours of infection.  This early detection allows medical professionals to diagnose and treat 
patients, who are infected with organisms such as human immunodeficiency virus (HIV), 
hepatitis B virus (HBV), and hepatitis C virus (HCV), with greater success.  The use of controls, 
including NATtrol™-treated microorganisms, in these highly sensitive PCR assays avoids false-
negative results and ensures accurate diagnosis of patients.  
 NATtrol™ stands for Nucleic Acid Testing Control.  NATtrol™ treatment renders 
microorganisms non-infectious while leaving them fully intact with their complete RNA or DNA 
genomes.  Because the organism is intact, NATtrol™-treated microorganisms can be used in 
PCR as full-process internal controls that are spiked into patient samples and co-extracted and 
co-amplified within the sample.  If the spiked NATtrol™ control returns expected results on the 
test, then the patient sample result can also be trusted.  
Here, we have performed studies to validate the use of NATtrol™-treated MS2 virus as a 
universal full-process internal molecular control.  In these studies, a quantitative, real-time, 
reverse-transcription PCR (qRT-PCR) assay was performed on the Roche LightCycler 480 
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instrument.  Validation studies to determine the assay working range and limit of detection were 
run first.  From these studies several dilutions of MS2 NATtrol™ were selected as standard 
curve calibrators, a low positive control, and a medium positive control.  Within-run and 
between-run precision studies were then performed on the standard curve calibrators, low 
positive control, and medium positive control.  Real-time stability, freeze-thaw (transport) 
stability, and open-vial (use-life) stability studies were also performed.  
All validation studies demonstrated the precision and stability of the MS2 NATtrol™ 
molecular control to have a coefficient of variation less than 5% with no loss in reactivity under 
all conditions.  Additionally, we demonstrated the use of the MS2 NATtrol™ control as a full-
process internal control on a multiplexed respiratory assay on the Luminex100 platform. 
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 1 
Introduction 
 
Molecular diagnostics  
Molecular diagnostics refers to the use of molecular biology, including the polymerase 
chain reaction (PCR), in medical testing.  PCR testing is ideal for molecular diagnostics because 
it is highly sensitive; PCR amplifies small amounts of nucleic acids found in patient samples and 
allows for the detection of infectious diseases within hours of infection.  This early detection 
allows medical professionals to diagnose and treat patients with greater success.  Molecular 
diagnostic PCR assays are often multiplexed, using multiple sets of primers in order to test for 
multiple targets simultaneously (1, 2, 3).  In molecular diagnostics, PCR is used not only to test 
patient samples for and then diagnose patients with various infectious diseases, including human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), but 
quantitative PCR is also used to monitor the progression of infectious diseases in patients as well 
as the progression of therapy for these diseases (4, 5).  
 In molecular diagnostic PCR, it is essential to use internal controls in order to avoid false-
negative results.  A false-negative test result occurs when a patient sample is called negative for 
a particular target, but that target actually is present in the patient sample.  In any PCR assay, 
false-negatives can result from human or machine error or the presence of amplification 
inhibitors.  As has been reiterated on many occasions, in molecular diagnostic PCR, the use of 
internal controls throughout the sample preparation and PCR procedures is essential in order to 
avoid false-negative results and ensure accurate diagnosis of patients (2, 4, 6).  It has been 
suggested that internal controls should be required for all molecular diagnostic PCR assays (6); 
however, although internal controls are often included in commercially produced kits for PCR, 
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home-brew, or in-house, PCR assays often do not include internal controls, sometimes because 
there are no appropriate internal controls available to use with the target(s) of interest (1, 7, 8).  
Therefore, there is a need for a readily available internal control that is safe to work with, can 
control for the entire sample preparation and PCR procedures, and can be used universally with 
all patient samples, with all tests, and on all testing platforms.  Such an internal control could be 
used with any available molecular diagnostic PCR test in order to avoid false-negative results 
and ensure accurate diagnosis and treatment of patients.  
 
Polymerase chain reaction (PCR)  
Polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR)  
 PCR was first described in 1985 by Saiki et al., and it was then described again in 1987 
by Mullis and Faloona (9, 10).  PCR exponentially amplifies small amounts of nucleic acids, 
which can be detected only after being amplified.  In PCR, a DNA sequence of interest, also 
called a target, is amplified by the use of forward and reverse oligonucleotide primers that are 
complementary to, and therefore anneal to, nucleic acid sequences at the two ends of that DNA 
sequence of interest (10).  PCR consists of repeated cycles of denaturation, annealing, and 
extension.  Denaturation of double-stranded DNA (dsDNA)–the separation of the two strands of 
dsDNA–happens at reaction temperatures greater than 90ºC.  Annealing of oligonucleotide 
primers to the single-stranded DNA (ssDNA) template happens at reaction temperatures of 50-
75ºC.  Extension of the primers by a DNA polymerase enzyme, synthesizing a new strand of 
DNA that is complementary to the target, happens at reaction temperatures of approximately 60-
80ºC, depending on the optimal temperature for the particular DNA polymerase used in the assay.  
In this way, in a perfect reaction, the amount of the target exactly doubles after every cycle (3, 10, 
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11, 12).  Many variables, including the concentration of the starting DNA template, the reaction 
conditions, and the presence of inhibitors, affect this amplification (5, 13, 14).  
To amplify an RNA target, reverse transcription (RT) must be performed first, and then 
PCR can be performed.  This is called reverse transcription PCR (RT-PCR).  In RT, an 
oligonucleotide primer anneals to the RNA target, and a reverse transcriptase synthesizes a 
strand of DNA that has a sequence complementary to the RNA target; this DNA strand is called 
complementary DNA (cDNA).  The cDNA is then amplified in PCR in the same way as any 
other strand of DNA, as described above.  RT-PCR can be either a two-step reaction or a one 
step-reaction.  In two-step RT-PCR, two separate enzymes–a reverse transcriptase and a DNA 
polymerase–are used for reverse transcription and PCR, respectively.  In one-step RT-PCR, one 
enzyme that has both reverse transcriptase and DNA polymerase activity is used for both reverse 
transcription and PCR.  Tth DNA polymerase is an example of an enzyme that has both reverse 
transcriptase and DNA polymerase activity (15).    
 
Real-time PCR (qPCR) and real-time RT-PCR (qRT-PCR)  
 A PCR or RT-PCR assay can be either qualitative or quantitative.  In a qualitative PCR or 
RT-PCR assay, the result is reported as either positive, meaning the nucleic acid target was 
detected, or negative, meaning the nucleic acid target was not detected.  Higuchi et al. first 
described quantitative PCR, also referred to as real-time PCR, in 1992 (16).  In a quantitative 
PCR (qPCR) or RT-PCR (qRT-PCR) assay, the abundance of the nucleic acid target is measured 
and reported, often as the initial concentration of the target nucleic acid sequence in the sample 
(5, 12, 17).  Quantitative PCR is also referred to as real-time PCR because the amount of nucleic 
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acid target present in the sample is monitored throughout the amplification, in real time, through 
the use of fluorogenic probes (5, 12, 18, 19, 20).  
 In 1991, Holland et al. first described the use of fluorogenic probes to detect PCR 
products (21).  In real-time PCR, a fluorogenic probe is an oligonucleotide sequence labeled with 
a reporter fluorescent dye at its 5′ end and a quencher dye at its 3′ end.  The nucleic acid 
sequence of the probe is complementary to, and therefore anneals to, a nucleic acid sequence 
within the target sequence (21, 22, 23, 24).  Before amplification, the probe is in tact, and the 
reporter and quencher are close enough in proximity that the quencher suppresses the fluorescent 
emission of the reporter via fluorescence resonance energy transfer (FRET) (5, 18, 23, 24, 25).  
During the annealing step of PCR, when the forward and reverse primers anneal to the target 
sequence, the probe also anneals to the target sequence (24).  During the extension step of PCR, 
as the DNA polymerase is extending the primer, 5′-nuclease activity of the DNA polymerase 
cleaves the probe, separating the reporter and the quencher from each other.  This decoupling of 
the reporter and the quencher means that the quencher no longer suppresses the fluorescent 
emission of the reporter, so there is an increase in fluorescence emission from the reporter (5, 18, 
21, 23, 24, 26).  As the repeated cycles of amplification progress, PCR product accumulates, and 
the increase in the fluorescence of the reporter dye correlates with the increase in PCR product.  
This fluorescence is continuously monitored and measured throughout the cycling (5, 12, 16, 18, 
21, 24).   
 The Roche LightCycler® 480 is an instrument used frequently in real-time PCR.  Real-
time PCR assays on the LightCycler® 480 utilize fluorogenic hydrolysis probes, like those 
described above, and the LightCycler® 480 monitors and measures the fluorescence of the 
reporter dye throughout the cycling.  This instrument quantifies the amount of target in a sample 
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by assigning it a crossing point (Cp) value based on the cycle at which the target is first detected 
in the sample during the cycling (when the fluorescence of the sample rises around the 
background fluorescence of the probe system) and then using a standard curve with calibrators of 
known concentrations of the target to calculate the concentration of the target in the sample (24).  
 Fluorescence can be detected through a closed tube or another closed system, meaning 
that, in real-time PCR, no post-PCR processing of the PCR product is required for its detection.  
This ability to measure fluorescence through a closed tube is what allows for the PCR product to 
be detected in real time, rather than at the end of the amplification, and, because the reaction 
vessel does not need to be opened, it reduces the potential for contamination of the laboratory 
with amplified PCR product, which could contaminate future PCR runs (16, 18, 26).  Additional 
advantages to real-time PCR include that it is more rapid and more sensitive than regular PCR 
(3).  
 
False-negatives in PCR  
 False-negative results are a problem with all PCR assays, especially in molecular 
diagnostics.  A false-negative result happens when a sample tests negative for a target but 
actually is positive for that target.  False-negative results can occur as a result of human or 
machine error or as a result of the presence of deoxyribonucleases (DNases), which catalyze the 
degradation of DNA, ribonucleases (RNases), which catalyze the degradation of RNA, or 
inhibitors of PCR (6, 8, 27, 28).  Inhibitors of PCR are found in many different kinds of patient 
samples, including blood, urine, and feces (27, 29, 30).  For instance, heme, which is found in 
blood, inhibits PCR (27, 31, 32, 33), and heparin is another PCR inhibitor that may be found in 
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patient blood samples (27, 32, 33, 34).  Also, urea is a PCR inhibitor found in patient urine 
samples (27, 33, 35).  
 False-negative results can be avoided by using internal controls.  If an internal control is 
not included in a PCR assay, and the assay returns the result that a sample is negative for the 
target of interest, the sample is either actually negative for the target of interest, or the PCR 
failed due to error or inhibition.  Because there is no internal control, it is not clear which of 
those two situations is the case; however, it is generally assumed that the sample is negative for 
the target of interest.  Such a false-negative result is particularly problematic in molecular 
diagnostics, where it would result in the patient not receiving the correct diagnosis and 
appropriate treatment.  However, if an internal control is included in the PCR assay, this 
incorrect diagnosis can be avoided.  If an assay returns the result that the sample is positive for 
the internal control and negative for the target of interest, this result gives confidence that the 
assay ran as expected and the sample is actually negative for the target of interest.  On the other 
hand, if an assay returns the result that the sample is negative for both the internal control and the 
target of interest, this result indicates that the PCR failed due to error or the presence of PCR 
inhibitors.  Therefore, this sample should be tested again because it may actually be positive for 
the target of interest.  
 
Internal molecular controls  
 As has been discussed above, it is important to use internal controls in molecular 
diagnostic PCR assays in order to avoid false-negative results and the resulting inaccurate 
diagnosis and treatment of patients.  Although internal controls are often provided in 
commercially available assays, home-brew assays often do not include internal controls (8).  
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Characteristics of internal controls that affect their utility include whether the control is 
competitive or noncompetitive with the target of interest and whether the control is an artificial 
nucleic acid sequence or a whole virus.  
 
Competitive internal controls vs. noncompetitive internal controls  
 The two main strategies for internal controls in molecular diagnostics are competitive 
internal controls and noncompetitive internal controls.  A competitive internal control is 
amplified with the same set of primers as the target; the internal control and target compete for 
these primers (5, 6, 36).  Many publications have described the use of competitive internal 
controls in PCR (7, 13, 14, 27, 37, 38, 39, 40, 41).  However, there are disadvantages to using 
competitive internal controls.  For instance, the competition between the internal control and the 
target can lower the efficiency of the amplification (6).  Additionally, because multiplexed PCR 
assays require several sets of primers in order to test for multiple targets simultaneously, 
competitive internal controls are not compatible with multiplexed PCR assays, which are 
appealing in molecular diagnostics (1).  Noncompetitive internal controls, on the other hand, are 
compatible with multiplexed PCR assays and are therefore a better choice of internal control for 
molecular diagnostics.  A noncompetitive internal control is amplified with a set of primers that 
is different from the set of primers that the target is amplified with (6).  
 
Artificial nucleic acid sequences vs. whole viruses  
 Competitive internal controls are most often artificial DNA or RNA fragments (4, 14, 40, 
41, 42), whereas both artificial nucleic acid sequences and whole viruses are used as 
noncompetitive internal controls.  Armored RNA®, which consists of an RNA sequence 
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packaged into the viral coat proteins of MS2 bacteriophage (7, 43, 44), is commonly used as a 
noncompetitive internal control (19, 20, 43, 44, 45).  The major disadvantage to using artificial 
DNA and RNA sequences as internal controls is that, although they can control for the 
amplification of samples, because they are not whole viruses, they do not behave similarly to 
target viruses during extraction and therefore do not control for the extraction of samples as well 
as whole viruses do (2).  
 Many publications have described the use of the whole MS2 virus as a noncompetitive 
internal control for both the extraction and the amplification of samples, including norovirus, 
enterovirus, influenza, HCV, and hepatitis A virus (HAV) samples, as well as many other 
samples (8, 46, 47, 48).  Other whole viruses used as noncompetitive internal controls for both 
the extraction and the amplification of samples have included T4 bacteriophage (8, 49) and seal 
herpesvirus type-1 (2, 50).  These viruses were selected for various reasons, including that they 
do not infect humans and are therefore safer to work with than viruses that do infect humans (2).  
 
Ideal characteristics of internal controls  
 Ideally, internal controls should control for every step of the testing process, including 
both extraction and amplification (7, 48).  Internal controls should also be stable, noninfectious, 
absent from clinical samples, and suitable for use in many different assays (1, 7).  Although 
whole viruses used as internal controls can control for the entire testing process, they are often 
dangerous to work with because of the risk of the individual performing the PCR assay being 
infected.  NATtrol™ products are noninfectious whole viruses that satisfy these criteria for ideal 
internal controls.  
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NATtrol™ (Nucleic Acid Testing Control)  
The first NATtrol™ molecular controls were developed in 1999 at ZeptoMetrix 
Corporation, and there are now over 400 NATtrol™-treated organisms, which include bacteria, 
viruses, fungi, and parasites.  NATtrol™ is a patented treatment procedure that renders 
microorganisms noninfectious and therefore safe to work with, and because it does not damage 
these microorganisms or their nucleic acids, NATtrol™-treated microorganisms can be used as 
full-process internal molecular controls.  
 Before NATtrol™ was developed, the methods to inactivate organisms included methods 
such as heat treatment and chemical detergents, which destroyed organisms and their nucleic 
acids.  Because the nucleic acids were destroyed, organisms inactivated with these techniques 
could not be used as molecular controls.  Therefore, controls were formulated with infectious 
disease state plasma, which is dangerous to work with.  Other disadvantages to using infectious 
disease state plasma as controls included that these controls could only be used one time, had to 
be kept frozen, and required both dry ice and infectious shipping.  Thus, there was a need for 
controls that were both safe to work with and could control for the entire testing process.  
 NATtrol™ treatment modifies the surface proteins of microorganisms in such a way that 
they are rendered unable to bind to a host cell.  Therefore, NATtrol™-treated microorganisms 
are noninfectious and safe to work with.  Additionally, NATtrol™ treatment leaves the 
microorganism’s genome fully intact.  Because NATtrol™ treatment does not damage the 
microorganism’s nucleic acids, the microorganism will still function in a molecular assay and 
therefore can be used as a molecular control.  Because they are whole viruses, NATtrol™-treated 
microorganisms can be used as full-process internal controls, meaning that the NATtrol™-
treated microorganism is spiked into the patient sample prior to extraction and is co-extracted 
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and co-amplified with the target of interest in the patient sample.  NATtrol™-treated 
microorganisms are also refrigerator stable.  Many publications have described the use of 
NATtrol™-treated microorganisms as controls, including the use of the NATtrol™-treated 
respiratory viruses in the NATtrol™ Respiratory Validation Panel NATRVP-2 as controls (51, 
52), the use of samples from the NATtrol™ Clostridium difficile Verification Panel as controls 
in verification and reproducibility studies (53), and the use of HIV NATtrol™ as a control for 
RNA quantification (54).  
 
NATtrol™-treated MS2 virus as a universal full-process internal control  
 In this project, studies were performed to validate the use of NATtrol™-treated MS2 
virus as a universal full-process internal molecular control.  MS2 bacteriophage is a positive-
sense single-stranded RNA virus that is a member of the Leviviridae family and infects male 
Escherichia coli bacteria.  The MS2 genome has 3569 nucleotides, and it encodes for four 
proteins: the replicase protein, the coat protein, the lysis protein, and the maturation protein (55, 
56).  MS2 virus does not infect humans or animals and is therefore not found in patient samples.  
MS2 virus is also stable and easily propagated (46, 47).  Because of these characteristics, MS2 
virus is an ideal candidate for a universal full-process internal control.  
 The studies performed to validate the MS2 NATtrol™ molecular control included studies 
to determine the assay working range and limit of detection, as well as within-run and between-
run precision studies performed for five standard curve calibrators, a low positive control, and a 
medium positive control, and also real-time, freeze-thaw (transport), and open-vial (use-life) 
stability studies.  These validation studies were performed using a one-step qRT-PCR assay on 
the Roche LightCycler® 480 instrument.   
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 The MS2 NATtrol™ full-process internal molecular control can be used universally with 
all patient samples and across all testing platforms.  This molecular control can be used 
commercially to enhance the reliability of molecular testing data.  Because of its universality, the 
MS2 NATtrol ™ molecular control can be used with any patient sample and any available PCR 
test, and the use of this control in molecular diagnostics will avoid false-negative results and 
ensure accurate diagnosis and treatment of patients.  
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Materials and Methods 
 
NATtrol™-treated MS2 virus  
 At ZMC–Buffalo, a lot of NATtrol™-treated MS2 virus was manufactured according to 
ZMC standard operating procedures (SOPs).  This lot of MS2 NATtrol™ was quantified at 
ZMC–Buffalo, and it was then shipped to ZMC–Franklin to be used in this project.  This single 
lot of MS2 NATtrol™ was used in all of the studies performed in this project and presented here.  
 
MS2 virus RNA extraction  
 The QIAGEN® QIAamp® Viral RNA Mini Kit was used for all of the extractions of 
MS2 NATtrol™ performed for the range validation studies, precision studies, and stability 
studies.  The procedure detailed in the QIAamp® Viral RNA Mini Handbook was followed.  In 
step 2, 140µL of MS2 NATtrol™ was added to the microcentrifuge tube.  Step 10, placing the 
QIAamp® Mini column in a new collection tube and centrifuging at full speed for 1 minute, was 
performed as recommended.  The RNA was eluted in 60µL of Buffer AVE, as directed, and was 
stored at -20ºC until being tested with the MS2 PCR assay on the Roche LightCycler 480.  
 
MS2 virus one-step qRT-PCR assay on the Roche LightCycler® 480  
 The MS2 PCR assay performed in the range validation studies, precision studies, and 
stability studies performed in this project was an MS2 virus one-step qRT-PCR assay performed 
on the Roche LightCycler® 480 Instrument.  Scientists at ZMC–Buffalo graciously provided this 
MS2 PCR assay, including the cycling protocol, master mix recipe, primers, and probe.  The 
Roche LightCycler® 480 RNA Master Hydrolysis Probes kit was used for this MS2 PCR assay.  
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ZMC SOPs and the LightCycler® 480 RNA Master Hydrolysis Probes kit package insert were 
followed, with the instructions of the ZMC SOPs superseding the instructions of the 
LightCycler® 480 RNA Master Hydrolysis Probes kit package insert.   
The MS2 PCR assay was a 25µL reaction, consisting of 20µL of master mix and 5µL of 
template.  The reagents included in the master mix for this MS2 PCR assay included PCR-grade 
deionized water, MS2 Taq forward and reverse primers, MS2 Taq probe, activator, and 
LightCycler® RNA Master Hydrolysis Probes.  The components of the master mix and their 
volumes per reaction are listed in Table I.  The enzyme in this MS2 PCR assay was Tth DNA 
polymerase, which catalyzes both the reverse transcription of RNA and the amplification of 
cDNA.  The cycling protocol for the MS2 PCR assay on the Roche LightCycler® 480 included 
uracil DNA glycosylase (UDG), reverse transcription (RT), and HotStart steps, followed by 45 
cycles of amplification.  This cycling protocol is listed in Table II.  
 The runs of this MS2 PCR assay performed for the working range validation study were 
qualitative, whereas all of the other runs of this MS2 PCR assay performed in this project were 
quantitative.  Excluding the initial quantification of the lot of MS2 NATtrol™ at ZMC–Buffalo 
following manufacture, all of the quantitative runs performed in this project used a five-point 
standard curve that is detailed in Table III.  The calibrators of this five-point standard curve were 
of the following dilutions: MS2 NATtrol™ neat (1:5), MS2 NATtrol™ 1:10, MS2 NATtrol™ 
1:100, MS2 NATtrol™ 1:10,000, and MS2 NATtrol™ 1:500,000.  
 
Primer and probe design  
 The primers and probe utilized in the MS2 PCR assay were manufactured by Integrated 
DNA Technologies (Coralville, Iowa) and had been previously designed by scientists at ZMC–
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Buffalo, who graciously provided them for use in this project.  As part of the designing of these 
primers and probe, the MS2 bacteriophage sequence was obtained from NCBI 
(www.ncbi.nlm.nih.gov), where its accession number is GQ153927.1.  A BLAST nucleotide 
query (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was also performed for the sequences of the MS2 
bacteriophage genome that the MS2 Taq forward primer, MS2 Taq reverse primer, and MS2 Taq 
probe target, in order to check the degree of nucleotide sequence homology.  
 The MS2 Taq primers target a 61bp region in the MS2 bacteriophage replicase gene.  The 
replicase gene spans a 1638bp region of the MS2 bacteriophage genome, from nucleotide 1761 
through nucleotide 3398.  The MS2 Taq forward primer is an oligonucleotide of 16 DNA bases 
that targets nucleotides 3169 through 3184 of the MS2 bacteriophage genome; its sequence is as 
follows: 5′- TGC TCG CGG ATA CCC G-3′.  The MS2 Taq reverse primer is an oligonucleotide 
of 20 DNA bases that targets nucleotides 3210 through 3229 of the MS2 bacteriophage genome; 
its sequence is as follows: 5′- AAC TTG CGT TCT CGA GCG AT-3′.   
The MS2 Taq probe is a TaqMan, or hydrolysis probe.  It is an oligonucleotide of 24 
DNA bases, labeled with a 5′ HEX™ fluorescent probe and a 3′ Iowa Black® FQ quencher.  It 
targets nucleotides 3186 through 3209 of the MS2 bacteriophage genome, within the 61bp region 
of the replicase gene that the MS2 Taq primers target.  The sequence of the MS2 Taq probe is as 
follows: 5′- /5HEX/ ACC TCG GGT TTC CGT CTT GCT CGT /3IABkFQ/ -3′.  Figure 1 
presents a visual representation of where the MS2 Taq primers and probe target in the MS2 
bacteriophage genome.  
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Statistical analyses  
 Statistical analyses were performed with the LightCycler® 480 Software (Version 
1.5.0.39) and Microsoft Excel.  All runs of the MS2 PCR assay were first analyzed with absolute 
quantification analysis by the second derivative maximum method on the LightCycler® 480 
Software.  For all runs, this analysis generated Cp values and amplification curves for all of the 
samples.  In addition, for the quantitative runs, this analysis used the standard curve calibrators to 
generate a standard curve and then used this standard curve to generate concentrations of the 
samples.  For quantitative runs, the LightCycler® 480 Software also calculated statistics of the 
standard curve included in the run, including error, efficiency, slope, and y-intercept.  
 The LightCycler® 480 Software has initial testing criteria for the error and efficiency of 
the standard curve.  The LightCycler® 480 Instrument Operator’s Manual specifies that the error 
value–the mean squared error of the single data points fit to the regression line–must be less than 
0.2.  It does not define the range that the efficiency of the amplification reaction must fall within.  
A perfect efficiency is 2, where the amount of target nucleic acids exactly double with each 
amplification cycle.  For every quantitative run of the MS2 PCR assay in this project, the 
LightCycler® 480 calculated the error and efficiency of the standard curve.  
 Cp values and concentrations for all samples were exported from the LightCycler® 480 
Software as text files.  These data were then input to Microsoft Excel, and all data analyses 
described in following sections, including means, standard deviations, and coefficients of 
variation, were performed in Microsoft Excel.  The LightCycler® 480 Software assigns Cp 
values to all samples detected within the 45 cycles of amplification, with all samples detected 
within the last 5 cycles having uncertainty associated with them and being assigned a Cp value of 
40.  However, for the MS2 PCR assay described above and used throughout this project, a Cp 
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value of 37 was used as the cutoff for a significant positive, as was determined in the limit of 
detection study. 
 
Quantification of the MS2 NATtrol™ stock material  
 The MS2 NATtrol™ neat (1:5) stock material was quantified at ZMC–Buffalo according 
to the extraction procedure, MS2 PCR assay, and statistical analyses specified above, with the 
only difference being that a different standard curve than the one depicted in Table III was used.  
 
Range validation studies  
 Studies performed to validate the range of the MS2 PCR assay included a working range 
validation study and a limit of detection study.  
 
Working range validation  
 To validate the working range of the MS2 PCR assay, several qualitative runs were 
performed with various dilutions of MS2 NATtrol™ run in multiple replicates, as shown in 
Figure 2.  The dilutions of MS2 NATtrol™ included the following: neat (1:5), 1:10, 1:100, 
1:1,000, 1:10,000, 1:50,000, 1:100,000, 1:500,000, 1:1,000,000, 1:5,000,000, and 1:10,000,000.  
To create these dilutions of MS2 NATtrol™, as well as all of the other dilutions of MS2 
NATtrol™ used in this project, the MS2 NATtrol™ stock material was diluted with purified 
protein matrix supplied by the Manufacturing Lab at ZMC–Franklin.  No-template controls 
(NTCs) (PCR-grade deionized water) were also included in multiple replicates in each run.  Data 
from the several runs were collected, and, using Microsoft Excel, the mean Cp was calculated for 
each MS2 NATtrol™ dilution.  
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 From the results of this working range validation study, the dilutions of MS2 NATtrol™ 
to be the standard curve calibrators, low positive control, and medium positive control were 
selected.  Bulks of these MS2 NATtrol™ dilutions were manufactured by diluting the MS2 
NATtrol™ stock material with purified protein matrix, and these bulks were dispensed into vials 
and used in the studies that follow.  
 
Limit of detection  
 The limit of detection (LOD) study was performed to validate the cutoff of the MS2 PCR 
assay.  Various dilutions of MS2 NATtrol™ that were expected to be near the cutoff of the MS2 
PCR assay were tested in a quantitative run of the MS2 PCR assay.  These dilutions, which were 
produced by diluting the MS2 NATtrol™ stock material with purified protein matrix, are 
depicted in Figure 3.  As depicted in Figure 3, NTCs, the five standard curve calibrators, and the 
low and medium positive controls were also run.  Data were collected, and the mean Cp for each 
MS2 NATtrol™ dilution was calculated in Microsoft Excel.  The data were then plotted on a 
graph of MS2 NATtrol™ dilution vs. mean Cp, and this graph was used to determine the LOD 
of the MS2 PCR assay.  
 
Precision studies   
 The precision of MS2 NATtrol™ as a full-process internal molecular control was 
assessed by both within-run and between-run precision of each of the standard curve calibrators 
as well as the low and medium positive controls.  All of the runs of the MS2 PCR assay analyzed 
in the precision studies used the plate setup depicted in Figure 4.  Samples included the standard 
curve calibrators, the low and medium positive controls, NTCs (PCR-grade deionized water), 
 18 
negative controls (purified protein matrix), and additional replicates of the same MS2 NATtrol™ 
dilutions as the standard curve calibrators, run as unknown samples rather than as calibrators.  
The standard curve calibrators in the first three columns of the plate were used to quantify all of 
the other samples on the plate, including the low and medium positive controls.  These standard 
curve calibrators in the first three columns of the plate were utilized only for this purpose of 
creating a standard curve and quantifying other samples; data from these calibrators were not 
used to analyze the precision of the standard curve calibrators.  For all of the precision studies, 
the precision of the standard curve calibrators was analyzed using the data of the MS2 
NATtrol™ dilutions run as unknown samples.  
 For each of the standard calibrators, the low positive control, and the medium positive 
control, the within-run precision was analyzed individually for the same two runs of the MS2 
PCR assay that were performed on the same day.  These same two runs as well as two additional 
runs of the MS2 PCR assay were analyzed together for the between-run precision of all of these 
samples.   
 
Within-run precision of the standard curve calibrators  
 The within-run precision of each of the standard curve calibrators was analyzed for two 
individual runs, using the data of the MS2 NATtrol™ dilutions run as unknown samples.  The 
Cp values of each replicate of each sample were input to Microsoft Excel, where the mean, 
standard deviation, and CV were calculated for each standard curve calibrator for each of the two 
runs.  
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Between-run precision of the standard curve calibrators  
 The between-run precision of the standard curve calibrators was analyzed using the data 
of the MS2 NATtrol™ dilutions run as unknown samples over four runs of the MS2 PCR assay.  
These four runs were performed over three days, and each run had 12 replicates of each dilution 
of MS2 NATtrol™.  The Cp values of each replicate of each sample from all four runs were 
input to Microsoft Excel, where the mean, standard deviation, and CV were calculated for each 
standard curve calibrator over the four runs.  From this precision data, the acceptable range for 
each standard curve calibrator was calculated.  The minimum acceptable Cp value was calculated 
using the following formula: Mean – 3*(Standard Deviation).  The maximum acceptable Cp 
value was calculated using the following formula: Mean + 3*(Standard Deviation).  These 
acceptable ranges were then plotted on a graph of mean Cp vs. MS2™ NATtrol dilution, with 
the error bars at each point to represent the acceptable range for that MS2 NATtrol™ standard 
curve calibrator.  
 
Within-run precision of the low positive control  
 The within-run precision of the low positive control was analyzed for two individual runs.  
For each run, the concentrations of each replicate were input to Microsoft Excel, where the mean, 
standard deviation, and CV were calculated for the low positive control.  
 
Between-run precision of the low positive control  
 The between-run precision of the low positive control was analyzed using data from four 
runs of the MS2 PCR assay.  These four runs were performed over three days, and each run had 
three replicates of the low positive control.  The concentrations of each replicate from all four 
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runs were input to Microsoft Excel, where the mean, standard deviation, and CV were calculated 
for the low positive control over the four runs.  From this precision data, the acceptable range for 
the low positive control was calculated.  The minimum concentration was calculated using the 
following formula: Mean – 3*(Standard Deviation).  The maximum concentration was calculated 
using the following formula: Mean + 3*(Standard Deviation).   
 
Within-run precision of the medium positive control  
 The within-run precision of the medium positive control was analyzed for two individual 
runs.  For each run, the concentrations of each replicate were input to Microsoft Excel, where the 
mean, standard deviation, and CV were calculated for the medium positive control.  
 
Between-run precision of the medium positive control  
The between-run precision of the medium positive control was analyzed using data from 
four runs of the MS2 PCR assay.  These four runs were performed over three days, and each run 
had three replicates of the medium positive control.  The concentrations of each replicate from 
all four runs were input to Microsoft Excel, where the mean, standard deviation, and CV were 
calculated for the medium positive control over the four runs.  From this precision data, the 
acceptable range for the medium positive control was calculated.  The minimum concentration 
was calculated using the following formula: Mean – 3*(Standard Deviation).  The maximum 
concentration was calculated using the following formula: Mean + 3*(Standard Deviation).   
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Stability studies  
 Studies investigating the stability of the MS2 NATtrol™ molecular control included real-
time stability, freeze-thaw (transport) stability, and open-vial (use-life) stability.  In all three of 
these studies, the stability of various dilutions of MS2 NATtrol™ was assessed.  The dilutions of 
MS2 NATtrol™ analyzed in these studies were the same dilutions as the five standard curve 
calibrators.  The plate setups for the real-time stability, freeze-thaw (transport) stability, and 
open-vial (use-life) stability studies are presented in Figure 4, Figure 5, and Figure 6, 
respectively.  All three plate setups included the standard curve calibrators, the low and medium 
positive controls, NTCs (PCR-grade deionized water), negative controls (purified protein matrix), 
and additional replicates of the same MS2 NATtrol™ dilutions as the standard curve calibrators, 
run as unknown samples rather than as calibrators.  The MS2 NATtrol™ dilutions run as 
unknown samples were analyzed in all three of these stability studies.  
 
Real-time stability  
 Six runs of the MS2 PCR assay were included in the real-time stability study.  The last 
three runs were performed on 02/21/2014, 02/28/2014, and 03/04/2014 and used the plate setup 
depicted in Figure 4, as is explained above.  The first three runs were initially intended for use in 
the working range validation study, and it was later decided to include these runs in the real-time 
stability study as well.  Therefore, these first three runs, which were performed on 11/13/2013, 
11/20/2013, and 11/22/2013, used the plate setup for the working range validation study, which 
is depicted in Figure 2.  From these runs, only the following MS2 NATtrol™ dilutions were 
included in the real-time stability study: MS2 NATtrol™ Neat (1:5), MS2 NATtrol™ 1:10, MS2 
NATtrol™ 1:100, MS2 NATtrol™ 1:10,000, and MS2 NATtrol™ 1:500,000.  
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 For each run included in the real-time stability study, the Cp values of each replicate of 
each MS2 NATtrol™ dilution were input to Microsoft Excel, where the mean and standard 
deviation were calculated.  Each run was assigned a time, in days, where the first run (performed 
on 11/13/2013) was Time = 0 days, and the times of the other runs were measured as number of 
days since the first run.  For each MS2 NATtrol™ dilution, the mean Cp of each run was plotted 
on a graph of mean Cp vs. time (days), and, at each point, error bars were included to represent 
the standard deviation.  
 
Freeze-thaw (transport) stability  
 At the beginning of the freeze-thaw (transport) stability study, five vials of various 
dilutions of MS2 NATtrol™ were prepared to contain sufficient material for at least four 
extractions to be performed.  These five dilutions of MS2 NATtrol™ were the following: MS2 
NATtrol™ neat (1:5), MS2 NATtrol™ 1:10, MS2 NATtrol™ 1:100, MS2 NATtrol™ 1:10,000, 
and MS2 NATtrol™ 1:500,000.  MS2 NATtrol™ from each vial was extracted, prior to 
undergoing any freeze-thaw cycles.  The five vials then underwent a total of three freeze-thaw 
cycles, in which they were frozen at -80ºC and thawed at room temperature.  After each freeze-
thaw cycle, MS2 NATtrol™ from each vial was extracted.  In summary, samples were extracted 
prior to undergoing any freeze-thaw cycles, after undergoing one freeze-thaw cycle, after 
undergoing two freeze-thaw cycles, and after undergoing three freeze-thaw cycles.  A negative 
control (purified protein matrix) also underwent this same procedure along with the five MS2 
NATtrol™ dilutions.  
 Three replicates of each of the MS2 NATtrol™ dilutions, as well as the negative control, 
in each of these four stages of freeze-thaw cycles (having undergone no freeze-thaw cycles, one 
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freeze-thaw cycle, two freeze-thaw cycles, and three freeze-thaw cycles) were tested on one run 
of the MS2 PCR assay, with the plate setup depicted in Figure 5.  Also included on this plate 
were replicates of the standard curve calibrators, the low and medium positive controls, and an 
NTC (PCR-grade deionized water).  
 For each MS2 NATtrol™ dilution at each of the four stages of freeze-thaw cycles, the Cp 
values of each replicate were input to Microsoft Excel, where the mean and standard deviation 
were calculated.  For each MS2 NATtrol™ dilution, a graph of mean Cp vs. number of freeze-
thaw cycles was plotted, with each point on the graph representing the mean Cp of one of the 
four stages of freeze-thaw cycles of that dilution and error bars at each point representing the 
standard deviation.  
 
Open-vial (use-life) stability  
 At the beginning of the open-vial (use-life) stability study, five vials of various dilutions 
of MS2 NATtrol™ were prepared to contain sufficient material for at least four extractions to be 
performed. These five dilutions of MS2 NATtrol™ were the following: MS2 NATtrol™ neat 
(1:5), MS2 NATtrol™ 1:10, MS2 NATtrol™ 1:100, MS2 NATtrol™ 1:10,000, and MS2 
NATtrol™ 1:500,000.  These vials were stored at 2-8ºC throughout the study, and samples were 
extracted from these vials on four separate occasions, referred to here as the first, second, third, 
and fourth uses of the vial.  A negative control (purified protein matrix) also underwent this same 
procedure along with the five MS2 NATtrol™ dilutions.  
 Three replicates of each of the MS2 NATtrol™ dilutions, as well as the negative control, 
at each of these four stages of use of the vial (first, second, third, and fourth use of the vial) were 
tested on one run of the MS2 PCR assay, with the plate setup depicted in Figure 6.  Also 
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included on this plate were replicates of the standard curve calibrators, the low and medium 
positive controls, and an NTC (PCR-grade deionized water).  
 For each MS2 NATtrol™ dilution at each of the four stages of use of the vial, the Cp 
values of each replicate were input to Microsoft Excel, where the mean and standard deviation 
were calculated.   For each MS2 NATtrol™ dilution, a graph of mean Cp vs. vial usage was 
plotted, with each point on the graph representing the mean Cp of one of the four stages of the 
use of the vial of that dilution and error bars at each point representing the standard deviation.  
 
Using the MS2 NATtrol™ molecular control in the Luminex xTAG RVP Assay  
 The MS2 NATtrol™ molecular control was used as a full-process internal control for 
several respiratory virus samples tested on the Luminex100 instrument.  The samples, from the 
NATtrol™ Respiratory Validation Panel NATRVP-3 (ZeptoMetrix Corporation, Buffalo, NY), 
are listed in Table IV.  Samples were extracted with the QIAGEN® QIAamp® MinElute® Virus 
Spin Kit.  A multiplexed respiratory assay was performed with the Luminex xTAG Respiratory 
Viral Panel (RVP) Assay and the TaKaRa Taq™ Hot Start Kit.  The QIAamp® MinElute® 
Virus Spin Handbook and xTAG RVP package insert were followed, with some modifications.  
 Prior to the start of the extraction, for each sample listed in Table IV, 20µL of the MS2 
NATtrol™ medium positive molecular control, rather than the xTAG MS2 Internal Control 
supplied in the xTAG RVP kit, was spiked into 200µL of sample.  Then, 200µL of this 220µL 
sample and internal control mixture was extracted, following the QIAamp® MinElute® Virus 
Spin Handbook, with the following modifications.  Step 9, the addition of 500µL of Buffer AW1 
to the QIAamp® MinElute® spin column, followed by centrifugation at 8000 rpm (6000 x g) for 
1 minute, was performed.  Step 13, placing the QIAamp® MinElute® spin column in a new 2mL 
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collection tube and incubating at 56ºC for 3 minutes to dry the membrane, was not performed.  In 
step 14, 55µL of Buffer AVE was applied to the center of the membrane of the QIAamp® 
MinElute® spin column, incubated at room temperature for 5 minutes, and centrifuged at 14,000 
rpm (20,000 x g) for one minute, to elute the nucleic acid material.  The eluted nucleic acid 
samples were stored at -80ºC until being tested with the xTAG RVP Assay.  
 The samples tested with the xTAG RVP Assay included the nucleic acid samples that 
were previously extracted as well as three NTCs (PCR-grade deionized water) and a run control 
(lambda phage, supplied in the xTAG RVP kit).  These samples are listed in Table V.  The 
multiplexed respiratory assay was performed following the instructions in the xTAG RVP 
package insert.  Samples were tested on the Luminex100 platform, using the Luminex100 
Integrated System 2.3 software.  Data analysis was performed with the TDAS RVP-I (Version 
1.11) software.  
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Results 
 
Quantification of the MS2 NATtrol™ stock material  
 In this run of the MS2 PCR assay, performed at ZMC–Buffalo, the MS2 NATtrol™ neat 
(1:5) stock material was quantified at 9.73E+08 pfu/mL.  
 
Range validation studies  
 In all runs of the MS2 PCR assay included in the working range validation and limit of 
detection studies, all replicates of the NTCs (PCR-grade deionized water) were negative.  
Additionally, in all quantitative runs of the MS2 PCR assay included in the range validation 
studies, the error and efficiency of the standard curve met the initial testing criteria of the 
LightCycler® 480.  
 
Working range validation  
 The mean Cp of each MS2 NATtrol™ dilution tested in the working range validation 
study is listed in Table VI.  Figure 7 depicts examples of the amplification curves generated by 
the LightCycler® 480 Software in this working range study.  
 
Limit of detection  
Table VII lists the mean Cp value for each MS2 NATtrol™ dilution tested in the LOD 
study.  The MS2 NATtrol™ dilutions that tested at Cp 40 were detected within the last five 
cycles (cycles 40 through 45) of the amplification and had some uncertainty associated with 
them.  
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Precision studies  
In all runs of the MS2 PCR assay included in all of the precision studies, all replicates of 
the NTCs (PCR-grade deionized water) and the negative controls (purified protein matrix) were 
negative.  All other samples run, including the standard curve calibrators, the low and medium 
positive controls, and the MS2 NATtrol™ dilutions run as unknown samples, were positive, as 
expected.  Additionally, in all quantitative runs of the MS2 PCR assay included in the precision 
studies, the error and efficiency of the standard curve met the initial testing criteria of the 
LightCycler® 480.  
Figure 8 depicts examples of the amplification curves generated in the precision studies 
by the LightCycler® 480 Software for the standard curve calibrators.  In this figure, the maroon, 
aqua, yellow-green, blue, and bright red amplification curves correspond to replicates of the MS2 
NATtrol™ neat (1:5) dilution, MS2 NATtrol™ 1:10 dilution, MS2 NATtrol™ 1:100 dilution, 
MS2 NATtrol™ 1:10,000 dilution, and MS2 NATtrol™ 1:500,000 dilution, respectively.  Figure 
9 depicts examples of the amplification curves generated in the precision studies by the 
LightCycler® 480 Software for the low and medium positive controls.  In this figure, the yellow 
and gray amplification curves correspond to replicates of the MS2 NATtrol™ medium positive 
control (MS2 NATtrol™ 1:1,000 dilution) and MS2 NATtrol™ low positive control (MS2 
NATtrol™ 1:100,000 dilution), respectively.  
 
Within-run precision of the standard curve calibrators  
 The results of the within-run precision analysis of the standard curve calibrators of the 
first and second runs of the MS2 PCR assay that were analyzed in this study are shown in Table 
VIII and Table IX, respectively.  Each table includes the mean Cp, standard deviation, and CV 
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for each standard curve calibrator for that individual run.  In both runs, all five standard curve 
calibrators had a CV less than 5%.    
 
Between-run precision of the standard curve calibrators  
Table X shows the mean Cp, standard deviation, and CV for each standard curve 
calibrator over the four runs analyzed in the between-run precision study.  Over 48 replicates 
over the four runs, all standard curve calibrators had a CV less than 5%.  The acceptable range 
for each standard curve calibrator is listed in Table XI.  Figure 10 shows the acceptable range of 
each standard curve calibrator plotted on a graph of mean Cp vs. MS2 NATtrol™ dilution, with 
error bars at each point representing the acceptable range of that standard curve calibrator.  
 
Within-run precision of the low positive control  
 The results of the within-run precision analysis of the low positive control for the first 
and second runs of the MS2 PCR assay that were analyzed in this study are shown in Table XII 
and Table XIII, respectively.  Each table includes the mean concentration, standard deviation, 
and CV for the low positive control for that individual run.  In the first run, the low positive 
control had a CV of 17.8%, and in the second run, the low positive control had a CV of 16.4%.  
 
Between-run precision of the low positive control  
Table XIV shows the mean concentration, standard deviation, and CV for the low 
positive control over the four runs analyzed in the between-run precision study.  Over 12 
replicates over the four runs, the low positive control had a CV of 20.1%. The acceptable range 
for the low positive control is 1.69E+04 pfu/mL to 6.80E+04 pfu/mL, as shown in Table XV.  
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Within-run precision of the medium positive control  
 The results of the within-run precision analysis of the medium positive control for the 
first and second runs of the MS2 PCR assay that were analyzed in this study are shown in Table 
XVI and Table XVII, respectively.  Each table includes the mean concentration, standard 
deviation, and CV for the medium positive control for that individual run.  In the first run, the 
medium positive control had a CV of 9.0%, and in the second run, the medium positive control 
had a CV of 6.6%.  
 
Between-run precision of the medium positive control  
Table XVIII shows the mean concentration, standard deviation, and CV for the medium 
positive control over the four runs analyzed in the between-run precision study.  Over 12 
replicates over the four runs, the medium positive control had a CV of 28.8%.  The acceptable 
range for the medium positive control is 7.23E+05 pfu/mL to 1.00E+07 pfu/mL, as shown in 
Table XIX.   
 
Stability studies  
 In all runs of the MS2 PCR assay included in the real-time stability, freeze-thaw 
(transport) stability, and open-vial (use-life) stability studies, all replicates of the NTCs (PCR-
grade deionized water) and the negative controls (purified protein matrix) were negative.  All 
other samples run, including the standard curve calibrators, the low and medium positive 
controls, and the MS2 NATtrol™ dilutions run as unknown samples, were positive, as expected.  
Additionally, in all quantitative runs of the MS2 PCR assay included in the stability studies, the 
error and efficiency of the standard curve met the initial testing criteria of the LightCycler® 480.  
 30 
Real-time stability  
 For each MS2 NATtrol™ dilution analyzed in the real-time stability study, a graph of 
mean Cp vs. time (days) was plotted to show the change in the mean Cp over the time of the runs 
included in this study.  Figure 11, Figure 12, Figure 13, Figure 14, and Figure 15 show the 
graphs plotted for the MS2 NATtrol™ neat (1:5) dilution, the MS2 NATtrol™ 1:10 dilution, the 
MS2 NATtrol™ 1:100 dilution, the MS2 NATtrol™ 1:10,000 dilution, and the MS2 NATtrol™ 
1:500,000 dilution, respectively.  In each graph, each point represents the mean Cp of that 
dilution of MS2 NATtrol™ in one of the runs included in the study, and the error bars represent 
the standard deviation for that dilution of MS2 NATtrol™ in that run.  
 Over the course of the six runs of the MS2 PCR assay that were included in the real-time 
stability study, the mean Cp of the MS2 NATtrol™ neat (1:5) dilution varied over 0.95 Cp points.  
The mean Cp of the MS2 NATtrol™ 1:10 dilution varied over 0.72 Cp points.  The mean Cp of 
the MS2 NATtrol™ 1:100 dilution varied over 1.57 Cp points.  The mean Cp of the MS2 
NATtrol™ 1:10,000 dilution varied over 1.87 Cp points.  If all five data points are considered, 
the mean Cp of the MS2 NATtrol™ 1:500,000 dilution varied over 4 Cp points.  If the 40 Cp 
call in the run performed on 11/22/2013 is excluded, the mean Cp of the MS2 NATtrol™ 
1:500,000 dilution varied over 2.59 Cp points.  
 
Freeze-thaw (transport) stability  
For each MS2 NATtrol™ dilution analyzed in the freeze-thaw (transport) stability study, 
a graph of mean Cp vs. number of freeze-thaw cycles was plotted to show the change in the 
mean Cp over the four stages of freeze-thaw cycles (having undergone no freeze-thaw cycles, 
one freeze-thaw cycle, two freeze-thaw cycles, and three freeze-thaw cycles) included in this 
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study.  Figure 16, Figure 17, Figure 18, Figure 19, and Figure 20 show the graphs plotted for the 
MS2 NATtrol™ neat (1:5) dilution, the MS2 NATtrol™ 1:10 dilution, the MS2 NATtrol™ 
1:100 dilution, the MS2 NATtrol™ 1:10,000 dilution, and the MS2 NATtrol™ 1:500,000 
dilution, respectively.  In each graph, each point represents the mean Cp of that dilution of MS2 
NATtrol™ in one of the four stages of freeze-thaw cycles, and the error bars represent the 
standard deviation for that dilution of MS2 NATtrol™ in that stage.  
Over the course of the four stages of freeze-thaw cycles included in this study, the mean 
Cp of the MS2 NATtrol™ neat (1:5) dilution varied over 1.68 Cp points.  The mean Cp of the 
MS2 NATtrol™ 1:10 dilution varied over 1.86 Cp points.  The mean Cp of the MS2 NATtrol™ 
1:100 dilution varied over 1.38 Cp points.  The mean Cp of the MS2 NATtrol™ 1:10,000 
dilution varied over 0.57 Cp points.  The mean Cp of the MS2 NATtrol™ 1:500,000 dilution 
varied over 0.87 Cp points.  
 
Open-vial (use-life) stability  
For each MS2 NATtrol™ dilution analyzed in the open-vial (use-life) stability study, a 
graph of mean Cp vs. vial usage was plotted to show the change in the mean Cp over the four 
stages of use of the vial (first, second, third, and fourth use of the vial) included in this study.  
Figure 21, Figure 22, Figure 23, Figure 24, and Figure 25 show the graphs plotted for the MS2 
NATtrol™ neat (1:5) dilution, the MS2 NATtrol™ 1:10 dilution, the MS2 NATtrol™ 1:100 
dilution, the MS2 NATtrol™ 1:10,000 dilution, and the MS2 NATtrol™ 1:500,000 dilution, 
respectively.  In each graph, each point represents the mean Cp of that dilution of MS2 
NATtrol™ at one of the four stages of use of the vial, and the error bars represent the standard 
deviation for that dilution of MS2 NATtrol™ at that stage.  
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Over the course of the four stages of vial usage included in this study, the mean Cp of the 
MS2 NATtrol™ neat (1:5) dilution varied over 2.19 Cp points.  If only the mean Cp values of 
the second, third, and fourth uses of the vial are considered, the mean Cp of the MS2 NATtrol™ 
neat (1:5) dilution varied by 0.65 Cp points.  The mean Cp of the MS2 NATtrol™ 1:10 dilution 
varied over 0.58 Cp points.  The mean Cp of the MS2 NATtrol™ 1:100 dilution varied over 1.03 
Cp points.  The mean Cp of the MS2 NATtrol™ 1:10,000 dilution varied over 0.55 Cp points.  
The LighCycler® 480 called every replicate of the MS2 NATtrol™ 1:500,000 dilution at every 
stage of vial usage 40 Cp.  
 
Using the MS2 NATtrol™ molecular control in the Luminex xTAG RVP Assay  
 The results of the multiplexed respiratory assay that used the MS2 NATtrol™ medium 
positive control as a full-process internal control are presented in Table XX and Table XXI.  The 
run control was lambda phage, and the internal control was NATtrol™-treated MS2 virus.  For 
this assay, the cutoff for a sample to test positive is a median fluorescent intensity (MFI) of 300.  
All of the samples that were spiked with the MS2 virus internal control prior to extraction tested 
positive for the internal control.  Each member of the NATRVP-3 panel tested positive for the 
correct virus, and the negative control included in the NATRVP-3 panel tested positive only for 
the internal control.  All three NTCs were negative for all respiratory viruses, and the run control 
(lambda) was present only in the lambda sample.  
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Discussion 
 
Range validation studies  
 That all replicates of the NTCs (PCR-grade deionized water) included in all runs of the 
MS2 PCR assay analyzed in the range validation studies were negative indicates that there was 
no contamination of any of the master mixes and no cross-contamination from tube to tube or 
well to well at any time during the extraction or PCR procedures.  Additionally, that every 
standard curve met the initial testing criteria of the LightCycler® 480 indicates that every 
standard curve was valid.  
 
Working range validation  
 From the results of the working range validation study, it was determined that the 
working range of the MS2 PCR assay was the MS2 NATtrol™ neat (1:5) through the MS2 
NATtrol™ 1:500,000 dilution.  The dilutions of MS2 NATtrol™ that fall within this working 
range were reproducibly called positive in the MS2 PCR assay by the LightCycler® 480 
instrument.  That all NTCs tested negative indicated that there was no contamination of the 
master mix and no carryover contamination from tube to tube or well to well. 
 The MS2 NATtrol™ dilutions to be used for the standard curve calibrators, low positive 
control, and medium positive control were selected from the results of the MS2 NATtrol™ 
dilutions run in the working range validation study.  Table XXII shows the results of the working 
range validation study with the MS2 NATtrol™ dilutions selected as standard curve calibrators, 
low positive control, and medium positive control highlighted in yellow, pink, and green, 
respectively.  The five standard curve calibrators were selected to cover the entire working range 
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of the MS2 PCR assay.  MS2 NATtrol™ 1:100,000 dilution was selected as the low positive 
control because it falls close to the lower end of the working range of the MS2 PCR assay.  MS2 
NATtrol™ 1:1,000 dilution was selected as the medium positive control because it falls in the 
middle of the working range of the MS2 PCR assay.   
 
Limit of detection  
 To determine the LOD of the MS2 PCR assay, the data in Table VII was plotted on a 
graph of MS2 NATtrol™ dilution vs. mean Cp, as shown in Figure 26.  Figure 27 is a close-up 
of a selection of the graph in Figure 26.  This close-up view of the graph is necessary to 
determine where the curve starts to flatten.  Looking at all of the data (Figure 26), it is evident 
that, as the MS2 NATtrol™ dilution decreases and the mean Cp increases, the shape of the curve 
changes dramatically.  Looking at the close-up view of where this dramatic change occurs 
(Figure 27), it is evident that the curve starts to flatten at Cp 37.  Where the curve flattens, the 
sensitivity of the assay decreases because the changes in Cp value from one dilution to another 
are not significant enough that we can accurately measure these differences.  We see in both 
Figure 26 and Figure 27 that before Cp 37, the changes in Cp value from one dilution to another 
are significant, and we can accurately measure these differences.  Whereas, there is error 
associated with the measurements in Cp value where the curve flattens.  Therefore, because the 
sensitivity of the assay decreases where the curve flattens, and the curve begins to flatten at Cp 
37, Cp 37 is the LOD of the MS2 PCR assay.   
Table XXIII presents the results of the LOD study, with the determined LOD of the MS2 
PCR assay applied to these results.  Because the LOD of the assay is Cp 37, Cp values less than 
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37 are significant positive results for this assay.  Any Cp values greater than 37 are considered 
negative, even though the LightCycler® 480 was able to detect target present in these samples.   
 
Precision studies  
 That all replicates of the NTCs (PCR-grade deionized water) and the negative controls 
(purified protein matrix) were negative in all runs of the MS2 PCR assay included in the 
precision studies were negative indicates that there was no contamination of any of the master 
mixes and no cross-contamination from tube to tube or well to well at any time during the 
extraction or PCR procedures.  Additionally, that every standard curve met the initial testing 
criteria of the LightCycler® 480 indicates that every standard curve was valid.  
 
Within-run precision of the standard curve calibrators  
 To assess the within-run precision of the standard curve calibrators, the standard utilized 
was that, when analyzing Cp values, a CV less than 5% demonstrates precision.  In both runs of 
the MS2 PCR assay that were analyzed in this study, all five standard curve calibrators had a CV 
less than 5%.  Therefore, the within-run precision of all five standard curve calibrators was 
demonstrated in this study.  That all NTCs and negative controls in both runs tested negative also 
indicated that there was no contamination of the master mix in either run.  
 
Between-run precision of the standard curve calibrators  
 To assess the within-run precision of the standard curve calibrators, the standard utilized 
was that, when analyzing Cp values, a CV less than 5% demonstrates precision.  The results of 
the between-run precision study showed that all five standard curve calibrators had a CV less 
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than 5%.  Therefore, the between-run precision of all five standard curve calibrators was 
demonstrated in this study.  From the results of this study, the acceptable range of each standard 
curve calibrator was calculated.  An end user who uses the standard curve, low positive control, 
and medium positive control developed and validated in this project will use these acceptable 
ranges to ensure the validity of their test results.  
 
Within-run precision of the low positive control  
 Because concentrations, rather than Cp values, were analyzed in this study of the within-
run precision of the low positive control, unlike in the within-run precision study for the standard 
curve calibrators, there was no set cutoff for the CV to demonstrate precision.  For both runs of 
the MS2 PCR assay analyzed in this study, the low positive control had a low CV.  Therefore, 
the precision of the low positive control was demonstrated in this study.  
  
Between-run precision of the low positive control  
 In this study of the between-run precision of the low positive control, concentrations, 
rather than Cp values, were analyzed, thus there was no set cutoff for the CV to demonstrate 
precision.  The results of this study showed that the low positive control had a low CV over the 
four runs analyzed.  Therefore, the precision of the low positive control was demonstrated in this 
study.  Also, from the results of this study, the acceptable range of the low positive control was 
calculated.  Anyone who uses the standard curve, low positive control, and medium positive 
control developed and validated in this project will use this acceptable range of the low positive 
control to ensure the validity of their results.  
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Within-run precision of the medium positive control  
 As in the study of the within-run precision of the low positive control, in this study of the 
within-run precision of the medium positive control, because concentrations, rather than Cp 
values, were analyzed there was no set cutoff for the CV to demonstrate precision.  For both runs 
of the MS2 PCR assay analyzed in this study, the medium positive control had a low CV.  
Therefore, the precision of the medium positive control was demonstrated in this study.  
 
Between-run precision of the medium positive control 
 As in the study of the between-run precision of the low positive control, in this study of 
the between-run precision of the medium positive control, concentrations, rather than Cp values, 
were analyzed, thus there was no set cutoff for the CV to demonstrate precision.  The results of 
this study showed that the medium positive control had a low CV over the four runs analyzed.  
Therefore, the precision of the medium positive control was demonstrated in this study.  
Additionally, from the results of this study, the acceptable range of the medium positive control 
was calculated.  Anyone who uses the standard curve, low positive control, and medium positive 
control developed and validated in this project will use this acceptable range of the medium 
positive control to ensure the validity of their results.  
 
 That within-run and between-run precision were demonstrates for all five standard curve 
calibrators, the low positive control, and the medium positive control demonstrates the within-
run and between-run precision of the MS2 NATtrol™ molecular control overall.  
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Stability studies  
 That all replicates of the NTCs (PCR-grade deionized water) and the negative controls 
(purified protein matrix) were negative in all runs of the MS2 PCR assay included in the real-
time stability, freeze-thaw (transport) stability, and open-vial (use-life) stability studies were 
negative indicates that there was no contamination of any of the master mixes and no cross-
contamination from tube to tube or well to well at any time during the extraction or PCR 
procedures.  Additionally, that every standard curve met the initial testing criteria of the 
LightCycler® 480 indicates that every standard curve was valid.  
 
Real-time stability  
 To assess the real-time stability of the MS2 NATtrol™ molecular control, the standard 
utilized was that, when analyzing Cp values, if the mean Cp increases less than 2 Cp points, this 
is considered no loss in reactivity, and thus it demonstrates stability.  Because a higher Cp value 
indicates that a sample is less positive, an increase in Cp value over time signifies loss of 
reactivity of the material over time.  It is expected, in general, that any material will lose some 
reactivity over time, so it is expected that the mean Cp value of any material will gradually 
increase over time.  If the mean Cp increases less than 2 Cp points, the material is considered to 
have no loss in reactivity, and therefore, an increase of less than 2 Cp points demonstrates that 
the material is stable over the period of time that it was tested.  
In this real-time stability study, the following MS2 NATtrol™ dilutions demonstrated the 
stability of the MS2 NATtrol™ molecular control: MS2 NATtrol™ neat (1:5) dilution, MS2 
NATtrol™ 1:10 dilution, MS2 NATtrol™ 1:100 dilution, and MS2 NATtrol™ 1:10,000 dilution.  
Over the course of the six runs of the MS2 PCR assay included in this study, the mean Cp of 
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these MS2 NATtrol™ dilutions varied by less than 2 Cp points.  That the mean Cp increased less 
than 2 Cp points demonstrated that there was no loss in reactivity of any of these four MS2 
NATtrol™ dilutions.  Therefore, the results of this study for these four dilutions of the MS2 
NATtrol™ molecular control demonstrated the stability of the MS2 NATtrol™ molecular 
control.  
 The mean Cp of the MS2 NATtrol™ 1:500,000 dilution varied by more than 2 Cp points 
over the course of the six runs of the MS2 PCR assay included in this study.  If all five data 
points are considered, the mean Cp of the MS2 NATtrol™ 1:500,000 dilution varied over 4 Cp 
points.  If the 40 Cp call in the run performed on 11/22/2013 is excluded, the mean Cp of the 
MS2 NATtrol™ 1:500,000 dilution varied over 2.59 Cp points.  However, the accuracy of the 
Cp values measured for this dilution of MS2 NATtrol™ must be taken into consideration.   
Except for the run performed on 02/21/2014, all of the mean Cp values calculated for the 
MS2 NATtrol™ 1:500,000 dilution were greater than Cp 37, the LOD of the MS2 PCR assay, 
and therefore these mean Cp values have uncertainty associated with them.  Additionally, for the 
run performed on 11/22/2013, all replicates of the MS2 NATtrol™ 1:500,000 dilution were 
called by the LightCycler® 480 as Cp 40.  The LightCycler® 480 assigns a call of Cp 40 to all 
samples detected within the last five cycles of amplification (cycles 40 through 45), so this Cp 
value does not reflect the actual cycle at which the target was detected, and this Cp value has 
inherent uncertainty associated with it.  Because of the uncertainty associated with these mean 
Cp values, they not very accurate or reliable.  Therefore, it is not surprising that there is much 
greater variation in the mean Cp values of the MS2 NATtrol™ 1:500,000 dilution, compared to 
the other four MS2 NATtrol™ dilutions.  Additional data needs to be collected on the MS2 
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NATtrol™ 1:500,000 dilution so that all mean Cp values are less than Cp 37 and therefore 
within the LOD of the MS2 PCR assay and accurate, reliable data.  
Disregarding the MS2 NATtrol™ 1:500,000 dilution because of the uncertainty 
associated with the data generated for it, this real-time stability study demonstrated that the MS2 
NATtrol™ molecular control had no loss in reactivity over a period of 111 days and was 
therefore stable for these 111 days.   Therefore, the MS2 NATtrol™ molecular control is stable 
for at least a minimum of 111 days.  The MS2 NATtrol™ molecular control should continue to 
be tested to add data to this real-time stability study to determine how much time can pass before 
the MS2 NATtrol™ molecular control shows a loss in reactivity and is therefore no longer 
considered stable.   
 
Freeze-thaw (transport) stability  
 To assess the freeze-thaw (transport) stability of the MS2 NATtrol™ molecular control, 
the standard utilized was that, when analyzing Cp values, if the mean Cp increases less than 2 Cp 
points, this is considered no loss in reactivity, and thus it demonstrates stability.  Because a 
higher Cp value indicates that a sample is less positive, an increase in Cp value with repeated 
freeze-thaw cycles signifies loss of reactivity of the material with repeated freeze-thaw cycles.  It 
is expected, in general, that any material will lose some reactivity when it is repeatedly froze and 
thawed, so it is expected that the mean Cp value of any material will gradually increase over 
repeated freeze-thaw cycles.  If the mean Cp increases less than 2 Cp points, the material is 
considered to have no loss in reactivity, and therefore, an increase of less than 2 Cp points 
demonstrates that the material is stable over repeated freeze-that cycles.  
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 In this freeze-thaw (transport) stability study, all five MS2 NATtrol™ dilutions that were 
tested (MS2 NATtrol™ neat (1:5) dilution, MS2 NATtrol™ 1:10 dilution, MS2 NATtrol™ 
1:100 dilution, MS2 NATtrol™ 1:10,000 dilution, and MS2 NATtrol™ 1:500,000 dilution) 
demonstrated the stability of the MS2 NATtrol™ molecular control.  Over the course of the four 
stages of freeze-thaw cycles included in this study (having undergone no freeze-thaw cycles, one 
freeze-thaw cycle, two freeze-thaw cycles, and three freeze-thaw cycles), the mean Cp of each of 
these five MS2 NATtrol™ dilutions varied by less than 2 Cp points.  That the mean Cp increased 
less than 2 Cp points demonstrated that there was no loss in reactivity of any of these five MS2 
NATtrol™ dilutions.  Therefore, the results of this study demonstrated the stability of not only 
these specific five dilutions of the MS2 NATtrol™ molecular control but also the MS2 
NATtrol™ molecular control in general.  
 In general, for microorganisms that have not been NATtrol™-treated, repeated freeze-
thaw cycles cause decay and loss of reactivity, so these samples can often only be tested once.  
However, NATtrol™ treatment confers greater stability on microorganisms, thus, NATtrol™-
treated microorganisms can generally undergo repeated freeze-thaw cycles before experiencing a 
2 point drop in Cp value and therefore loss of reactivity.  This freeze-thaw (transport) stability 
study demonstrated that the MS2 NATtrol™ molecular control has no loss in reactivity after 
undergoing three freeze-thaw cycles, and therefore the MS2 NATtrol™ molecular control is 
stable for at least three freeze-thaw cycles.  
 
Open-vial (use-life) stability  
 To assess the open-vial (use-life) stability of the MS2 NATtrol™ molecular control, the 
standard utilized was that, when analyzing Cp values, if the mean Cp increases less than 2 Cp 
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points, this is considered no loss in reactivity, and thus it demonstrates stability. Because a higher 
Cp value indicates that a sample is less positive, an increase in Cp value with vial usage signifies 
loss of reactivity of the material with repeated vial usage.  If the mean Cp increases less than 2 
Cp points, the material is considered to have no loss in reactivity, and therefore, an increase of 
less than 2 Cp points demonstrates that the material is stable with repeated uses of the same vial 
of material.  
In this open-vial (use-life) stability study, the following MS2 NATtrol™ dilutions 
demonstrated the stability of the MS2 NATtrol™ molecular control: MS2 NATtrol™ 1:10 
dilution, MS2 NATtrol™ 1:100 dilution, and MS2 NATtrol™ 1:10,000 dilution.  Over the 
course of the four stages of use of the vial (first, second, third, and fourth use of the vial) 
included in this study, the mean Cp of these MS2 NATtrol™ dilutions varied by less than 2 Cp 
points.  That the mean Cp increased less than 2 Cp points demonstrated that there was no loss in 
reactivity of any of these three MS2 NATtrol™ dilutions.  Therefore, the results of this study for 
these three dilutions of the MS2 NATtrol™ molecular control demonstrated the stability of the 
MS2 NATtrol™ molecular control.  
 Over the course of all four stages of use of the vial, the LightCycler® 480 called all 
replicates of the MS2 NATtrol™ 1:500,000 dilution as Cp 40.  The LightCycler® 480 assigns a 
call of Cp 40 to all samples detected within the last five cycles of amplification (cycles 40 
through 45), so this Cp value does not reflect the actual cycle at which the target was detected, 
and this Cp value has inherent uncertainty associated with it.  Because of the uncertainty 
associated with these mean Cp values, they not very accurate or reliable.  Also, because this Cp 
40 call was made for all replicates of the MS2 NATtrol™ 1:500,000 dilutions all four stages of 
use of the vial, and this call does not reflect the actual cycle at which the target was detected, this 
 43 
data cannot be analyzed to assess the stability of the MS2 NATtrol™ 1:500,000 dilution over the 
course of repeated uses of the same vial of material.  Additional data must be collected; however, 
it is expected that this MS2 NATtrol™ 1:500,000 dilution would demonstrate stability similar to 
the other MS2 NATtrol™ dilutions tested here.  
 Over the course of the four stages of use of the vial, the mean Cp of the MS2 NATtrol™ 
neat (1:5) dilution varied over 2.19 Cp points.  Based on the criteria that an increase of less than 
2 Cp points demonstrates stability, the data for this MS2 NATtrol™ dilution does not 
demonstrate stability.  However, there are additional characteristics of this data that should be 
considered.  If there is loss in reactivity as the vial is used repeatedly, the mean Cp will increases 
with each use of the vial.  However, here, the greatest mean Cp value for the MS2 NATtrol™ 
neat (1:5) dilution was from the first use of the vial.  If only the mean Cp values of the second, 
third, and fourth uses of the vial are considered, the mean Cp of the MS2 NATtrol™ neat (1:5) 
dilution varied by only 0.65 Cp points, which is more consistent with the variation seen in the 
mean Cp values of the MS2 NATtrol™ 1:10 dilution, MS2 NATtrol™ 1:100 dilution, and MS2 
NATtrol™ 1:10,000 dilution.  Therefore, it is likely that the first data point for the MS2 
NATtrol™ neat (1:5) dilution is an outlier.  When only the mean Cp values of the second, third, 
and fourth uses of the vial are considered, the MS2 NATtrol™ neat (1:5) dilution demonstrates 
the stability of the MS2 NATtrol™ molecular control.  
 This open-vial (use-life) stability study demonstrated that the MS2 NATtrol™ molecular 
control had no loss in reactivity over four uses of the same vial of material.  Therefore, this study 
demonstrated that the MS2 NATtrol™ molecular control is stable for at least a minimum of four 
uses of the same vial of MS2 NATtrol™ molecular control.  
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 The real-time stability, freeze-thaw (transport) stability, and open-vial (use-life) stability 
studies demonstrated that five dilutions of the MS2 NATtrol™ molecular control were stable for 
111 days, four freeze-that cycles, and four uses of the same vial of MS2 NATtrol™ molecular 
control, respectively.  Therefore, these studies demonstrated that the MS2 NATtrol™ molecular 
control, at a minimum, is stable for at least 111 days, at least four freeze-thaw cycles, and at least 
four uses of the same vial of MS2 NATtrol™ molecular control.  
 
Using the MS2 NATtrol™ molecular control in the Luminex xTAG RVP Assay  
 All three NTCs were negative for all targets, the internal control, and the run control.  
Additionally, the run control (lambda) was present only in the lambda sample.  These results 
indicate that there was no contamination of any of the master mixes and no carryover 
contamination from tube to tube or well to well at any time during the extraction or PCR 
procedure.  
 For every sample that had the MS2 NATtrol™ medium positive control spiked into it as 
a full-process internal control–these samples are listed in Table IV–the internal control was 
present in the sample and was detected at a value above the cutoff for a positive (300 MFI).  
Each of the samples from NATRVP-3 also tested positive for the appropriate target(s).  The 
Influenza A H1N1 Strain: A/NY/02/2009 sample did not test positive for the H1 target, as may 
be expected; however, this is actually the expected result for this sample, as this assay cannot 
detect this particular strain (please see the Luminex xTAG RVP package insert for more details).   
 These results demonstrate that the MS2 NATtrol™ molecular control is compatible with 
all of the respiratory viruses tested here and that the MS2 NATtrol™ molecular control is 
compatible with the Luminex100 platform and the Luminex xTAG RVP Assay.  
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Conclusion 
 
NATtrol™-treated MS2 virus as a universal full-process internal control  
 In this project, studies were performed to validate the use of NATtrol™-treated MS2 
virus as a full-process internal molecular control that can be used universally with any patient 
sample, test, or testing platform.  Five MS2 NATtrol™ standard curve calibrators, an MS2 
NATtrol™ low positive control, and an MS2 NATtrol™ medium positive control were 
manufactured.  All validation studies demonstrated the precision and stability of the MS2 
NATtrol™ molecular control to have a coefficient of variation less than 5% with no loss in 
reactivity under all conditions.  The use of the MS2 NATtrol™ medium positive control as a 
full-process internal control on a multiplexed assay of various respiratory diseases was 
demonstrated with the Luminex xTAG RVP assay.  This MS2 NATtrol™ molecular control can 
now be used commercially to enhance the reliability of molecular testing data, allowing 
healthcare workers to more accurately diagnose and treat patients.  
 
Using the MS2 NATtrol™ molecular control  
 The MS2 NATtrol™ molecular control validated in this project can now be used 
commercially.  The reaction conditions of the MS2 PCR assay run here are common in many 
testing scenarios, so end users are able to incorporate this MS2 NATtrol™ molecular control into 
their already existing testing systems with only minor modifications, if any.  When an end user 
incorporates this MS2 NATtrol™ molecular control into his test, he will run the five-point 
standard curve developed here, and he will also spike all patient samples, prior to extraction, 
with either the MS2 NATtrol™ low positive control or the MS2 NATrol™ medium positive 
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control, whichever he determines is most appropriate for his test.  The first level of quality 
control for the end user’s test is that the mean Cp value of each standard curve calibrator must 
fall within the acceptable range specified in Table XI.  This standard curve will be used to 
quantify whichever full-process internal control–either the low positive control or the medium 
positive control–was included in every sample that it was spiked into.  The second level of 
quality control for the end user’s test is that the mean concentration of the full-process internal 
control in each patient sample must fall within the acceptable range specified in either Table XV 
(for the low positive control) or Table XIX (for the medium positive control).  
For the end user’s test to be valid, the mean Cp value of each MS2 NATtrol™ standard 
curve calibrator must fall within the acceptable range determined in this project, and the mean 
concentration of whichever full-process internal control–either the MS2 NATtrol™ low positive 
control or the MS2 NATtrol™ medium positive control–was included must, in each patient 
sample that it was spiked into, fall within the acceptable range determined in this project.   
 
Future directions  
 Future directions include continuing the real-time stability studies performed in this 
project.  It is expected that the MS2 NATtrol™ molecular control is stable for much longer than 
the 111 days of stability demonstrated in this project.  Therefore, the five MS2 NATtrol™ 
dilutions tested here–MS2 NATtrol™ neat (1:5), MS2 NATtrol™ 1:10, MS2 NATtrol™ 1:100, 
MS2 NATtrol™ 1:10,000, and MS2 NATtrol™ 1:500,000–should continue to be tested in 
multiple replicates on a regular basis.  When a 2 point drop in mean Cp is observed, the MS2 
NATtrol™ molecular control will no longer be considered stable.  Future directions may also 
 47 
include FDA IVD/CE marking of the MS2 NATtrol™ molecular control as part of the Molecular 
Diagnostics Division of ZeptoMetrix Corporation.  
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Tables 
 
 
 
 
 
 
 
 
 
 
 
Master Mix Component Volume added per reaction 
PCR-grade water 8.02µL 
MS2 Taq Primers 0.6µL 
MS2 Taq Probe 0.5µL 
Activator 1.63µL 
LightCycler® RNA Master Hydrolysis Probes 9.25µL 
Template  5µL 
 
Table I.  MS2 PCR assay master mix components. This table lists the components of the master 
mix for the MS2 PCR assay and the volume of each component to be added to the master mix 
per reaction.  The PCR-grade water, activator, and LightCycler® RNA Master Hydrolysis Probes 
were from the LightCycler® 480 RNA Master Hydrolysis Probes kit.  The activator contained 
Mn(OAc)2, and the LightCycler® RNA Master Hydrolysis Probes contained buffer, nucleotides, 
and Tth DNA polymerase.  The MS2 Taq primers were a 1:1 mixture of the MS2 Taq forward 
primer and the MS2 Taq reverse primer.  The MS2 Taq primers had a final concentration of 
300nM/reaction, and the MS2 Taq probe had a final concentration of 100nM/reaction.  
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Name Cycles Temperature Time 
Uracil DNA glycosylase 1 cycle 50ºC 1 minute 
Reverse Transcription 1 cycle 42ºC 1 minute 
HotStart 1 cycle 95ºC 10 minutes 
Amplification 
Denaturation 
Annealing 
Extension/Elongation 
45 cycles 
 
95ºC 
55ºC 
65ºC 
 
2 seconds 
20 seconds 
30 seconds 
 
Table II.  MS2 PCR assay cycling protocol.  The uracil DNA glycosylase (UDG) step prevented 
carry-over contamination, thereby preventing false-positive results.  The HotStart step activated 
the DNA polymerase activity of Tth DNA polymerase.  
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Standard Curve Calibrator Concentration (pfu/mL) 
MS2 NATtrol™ Neat (1:5) 9.73E+08 
MS2 NATtrol™ 1:10 4.87E+08 
MS2 NATtrol™ 1:100 4.87E+07 
MS2 NATtrol™ 1:10,000 4.87E+05 
MS2 NATtrol™ 1:500,000 9.73E+03 
 
Table III.  MS2 PCR assay standard curve calibrators. This table lists the standard curve 
calibrators utilized in the quantitative runs of the MS2 PCR assay as well as the concentrations of 
these calibrators.  When the MS2 NATtrol™ neat (1:5) stock material was manufactured at 
ZMC–Buffalo, this MS2 NATtrol™ neat (1:5) stock was quantitated at a concentration of 
9.73E+08 pfu/mL.  The other standard curve calibrators were produced by series dilutions of the 
MS2 NATtrol™ neat (1:5) stock material, and the concentrations of these calibrators were 
calculated based on the concentration of the MS2 NATtrol™ neat (1:5) stock material.   
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Sample Name Virus Strain 
Influenza A H1N1 Influenza A H1N1 A/NY/02/2009 
Influenza A H1N1 Influenza A H1N1 A/Singapore/63/04 
Influenza A H3N2 Influenza A H3N2 A/Victoria/3/75 
Influenza B Influenza B B/Yamanashu/166/98 
RSV A RSV A N/A 
RSV B RSV B CH93(18)-18 
Metapneumovirus Metapneumovirus Peru6-2003 
Parainfluenza 1 Parainfluenza 1 N/A 
Parainfluenza 2 Parainfluenza 2 N/A 
Parainfluenza 3 Parainfluenza 3 N/A 
Adenovirus 3 Adenovirus 3 N/A 
Enterovirus Enterovirus N/A 
Rhinovirus Rhinovirus N/A 
Coronavirus 229E Coronavirus 229E N/A 
Coronavirus SARS Cornavirus SARS N/A 
Coronavirus OC43 Coronavirus OC43 N/A 
Negative N/A N/A 
 
Table IV.  Samples included in the NATtrol™ Respiratory Validation Panel NATRVP-3.  These 
samples were spiked with the MS2 NATtrol™ medium positive molecular control and then 
extracted with the Qiagen QIAamp® MinElute® Virus Spin Kit.  
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Sample Name Virus Strain 
NTC (dH2O) N/A N/A 
Influenza A H1N1 Influenza A H1N1 A/NY/02/2009 
Influenza A H1N1 Influenza A H1N1 A/Singapore/63/04 
Influenza A H3N2 Influenza A H3N2 A/Victoria/3/75 
Influenza B Influenza B B/Yamanashu/166/98 
RSV A RSV A N/A 
RSV B RSV B CH93(18)-18 
Metapneumovirus Metapneumovirus Peru6-2003 
Parainfluenza 1 Parainfluenza 1 N/A 
NTC (dH2O) N/A N/A 
Parainfluenza 2 Parainfluenza 2 N/A 
Parainfluenza 3 Parainfluenza 3 N/A 
Adenovirus 3 Adenovirus 3 N/A 
Enterovirus Enterovirus N/A 
Rhinovirus Rhinovirus N/A 
Coronavirus 229E Coronavirus 229E N/A 
Coronavirus SARS Cornavirus SARS N/A 
Coronavirus OC43 Coronavirus OC43 N/A 
Negative N/A N/A 
Lambda N/A N/A 
NTC (dH2O) N/A N/A 
 
Table V.  Samples that were tested with the Luminex xTAG RVP assay on the Luminex100 
instrument.  These samples include the members of the NATtrol™ Respiratory Validation Panel 
NATRVP-3, three NTCs (PCR-grade deionized water), and a lambda run control (from the 
Luminex xTAG RVP kit).  
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Dilution Replicates Mean Cp 
MS2 NATtrol™ Neat (1:5) 24 19.52 
MS2 NATtrol™ 1:10 24 20.70 
MS2 NATtrol™ 1:100 24 24.50 
MS2 NATtrol™ 1:1,000 24 28.84 
MS2 NATtrol™ 1:10,000 24 32.92 
MS2 NATtrol™ 1:50,000 24 35.75 
MS2 NATtrol™ 1:100,000 24 36.74 
MS2 NATtrol™ 1:500,000 24 38.67 
MS2 NATtrol™ 1:1,000,000 24 39.30 
MS2 NATtrol™ 1:5,000,000 21 39.75 
MS2 NATtrol™ 1:10,000,000 13 39.65 
 
Table VI.  Working range validation study results.  This table presents the results of the working 
range validation study results, in the form of mean Cp values for various dilutions of MS2 
NATtrol™ tested in multiple replicates over a multiple runs of the MS2 PCR assay.  
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Sample Replicates Mean Cp 
MS2 NATtrol™ Neat (1:5) 3 18.96 
MS2 NATtrol™ 1:10 3 21.11 
MS2 NATtrol™ 1:100 3 25.31 
MS2 NATtrol™ 1:1,000 3 29.15 
MS2 NATtrol™ 1:10,000 3 33.25 
MS2 NATtrol™ 1:100,000 3 36.61 
MS2 NATtrol™ 1:500,000 9 39.56 
MS2 NATtrol™ 1:600,000 6 40 
MS2 NATtrol™ 1:800,000 6 40 
MS2 NATtrol™ 1:900,000 6 40 
MS2 NATtrol™ 1:1,000,000 6 40 
MS2 NATtrol™ 1:2,000,000 6 40 
MS2 NATtrol™ 1:3,000,000 6 40 
MS2 NATtrol™ 1:4,000,000 6 40 
MS2 NATtrol™ 1:5,000,000 6 40 
MS2 NATtrol™ 1:6,000,000 6 40 
MS2 NATtrol™ 1:8,000,000 6 40 
MS2 NATtrol™ 1:10,000,000 6 40 
 
Table VII.  Limit of detection study results.  This table presents the results of the LOD study, in 
the form of mean Cp values for the various MS2 NATtrol™ dilutions tested in one run of the 
MS2 PCR assay.    
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Standard Curve Calibrator Replicates Mean Cp Standard Deviation CV (%) 
MS2 NATtrol™ Neat (1:5) 12 19.15 0.07 0.4 
MS2 NATtrol™ 1:10 12 21.22 0.26 1.2 
MS2 NATtrol™ 1:100 12 25.58 0.13 0.5 
MS2 NATtrol™ 1:10,000 12 33.03 0.29 0.9 
MS2 NATtrol™ 1:500,000 12 38.50 0.53 1.4 
 
Table VIII.  Results of the within-run precision of the standard curve calibrators for the first run 
analyzed.  This table lists the replicates, mean Cp, standard deviation, and CV (as a percentage) 
for each of the five standard curve calibrators for the first run analyzed in the within-run 
precision study.  All standard curve calibrators had a CV less than 5%.   
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Standard Curve Calibrator Replicates Mean Cp Standard Deviation CV (%) 
MS2 NATtrol™ Neat (1:5) 12 19.23 0.10 0.5 
MS2 NATtrol™ 1:10 12 21.31 0.17 0.8 
MS2 NATtrol™ 1:100 12 25.24 0.14 0.6 
MS2 NATtrol™ 1:10,000 12 34.02 0.43 1.3 
MS2 NATtrol™ 1:500,000 12 39.37 0.54 1.4 
 
Table IX.  Results of the within-run precision of the standard curve calibrators for the second run 
analyzed.  This table lists the replicates, mean Cp, standard deviation, and CV (as a percentage) 
for each of the five standard curve calibrators for the second run analyzed in the within-run 
precision study.  All standard curve calibrators had a CV less than 5%.   
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Standard Curve Calibrator Replicates Mean Cp Standard Deviation CV (%) 
MS2 NATtrol™ Neat (1:5) 48 19.47 0.64 3.3 
MS2 NATtrol™ 1:10 48 21.19 0.30 1.4 
MS2 NATtrol™ 1:100 48 25.43 0.28 1.1 
MS2 NATtrol™ 1:10,000 48 33.22 0.75 2.3 
MS2 NATtrol™ 1:500,000 48 38.13 1.38 3.6 
 
Table X.  Results of the between-run precision study of the standard curve calibrators.  This table 
lists the mean Cp, standard deviation, and CV (as a percentage) for each of the five standard 
curve calibrators over 48 replicates over the four runs that were analyzed for the between-run 
precision study.  All standard curve calibrators had a CV less than 5%.   
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Standard Curve Calibrator Minimum Acceptable Cp Maximum Acceptable Cp 
MS2 NATtrol™ Neat (1:5) 17.55 21.39 
MS2 NATtrol™ 1:10 20.29 22.09 
MS2 NATtrol™ 1:100 24.59 26.27 
MS2 NATtrol™ 1:10,000 30.97 35.47 
MS2 NATtrol™ 1:500,000 33.99 42.27 
 
Table XI.  Acceptable range of each standard curve calibrator.  Using the results of the between-
run precision study for the standard curve calibrators, the acceptable range of each standard 
curve was calculated.  The minimum acceptable Cp value was calculated using the following 
formula: Mean – 3*(Standard Deviation).  The maximum acceptable Cp value was calculated 
using the following formula: Mean + 3*(Standard Deviation). 
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MS2 NATtrol™ Low 
Positive Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation CV (%) 
MS2 NATtrol™ 1:100,000 3 4.47E+04 7.97E+03 17.8 
 
Table XII.  Results of the within-run precision of the low positive control for the first run 
analyzed.  This table lists the replicates, mean concentration, standard deviation, and CV (as a 
percentage) for the low positive control for the first run analyzed in the within-run precision 
study.  
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MS2 NATtrol™ Low 
Positive Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation CV (%) 
MS2 NATtrol™ 1:100,000 3 5.01E+04 8.24E+03 16.4 
 
Table XIII.  Results of the within-run precision of the low positive control for the second run 
analyzed.  This table lists the replicates, mean concentration, standard deviation, and CV (as a 
percentage) for the low positive control for the second run analyzed in the within-run precision 
study.  
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MS2 NATtrol™ Low Positive 
Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation 
CV 
(%) 
MS2 NATtrol™ 1:100,000 12 4.24E+04 8.52E+03 20.1 
 
Table XIV.  Results of the between-run precision study of the low positive control.  This table 
lists the mean concentration, standard deviation, and CV (as a percentage) for the low positive 
control over 12 replicates over the four runs that were analyzed for the between-run precision 
study.  
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MS2 NATtrol™ Low 
Positive Control Dilution 
Minimum Acceptable 
Concentration 
Maximum Acceptable 
Concentration 
MS2 NATtrol™ 1:100,000 1.69E+04 6.80E+04 
 
Table XV.  Acceptable range of the low positive control. Using the results of the between-run 
precision study, the acceptable range of the low positive control was calculated.  The minimum 
acceptable concentration was calculated using the following formula: Mean – 3*(Standard 
Deviation).  The maximum acceptable concentration was calculated using the following formula: 
Mean + 3*(Standard Deviation).  
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MS2 NATtrol™ Medium 
Positive Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation CV (%) 
MS2 NATtrol™ 1:1,000 3 5.78E+06 5.20E+05 9.0 
 
Table XVI.  Results of the within-run precision of the medium positive control for the first run 
analyzed.  This table lists the replicates, mean concentration, standard deviation, and CV (as a 
percentage) for the medium positive control for the first run analyzed in the within-run precision 
study.  
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MS2 NATtrol™ Medium 
Positive Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation CV (%) 
MS2 NATtrol™ 1:1,000 3 5.57E+06 3.66E+05 6.6 
 
Table XVII.  Results of the within-run precision of the medium positive control for the second 
run analyzed.  This table lists the replicates, mean concentration, standard deviation, and CV (as 
a percentage) for the medium positive control for the second run analyzed in the within-run 
precision study.  
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MS2 NATtrol™ Medium Positive 
Control Dilution Replicates 
Mean 
Concentration 
Standard 
Deviation 
CV 
(%) 
MS2 NATtrol™ 1:1,000 12 5.37E+06 1.55E+06 28.8 
 
Table XVIII.  Results of the between-run precision study of the medium positive control.  This 
table lists the mean concentration, standard deviation, and CV (as a percentage) for the medium 
positive control over 12 replicates over the four runs that were analyzed for the between-run 
precision study.  
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MS2 NATtrol™ Medium 
Positive Control Dilution 
Minimum Acceptable 
Concentration 
Maximum Acceptable 
Concentration 
MS2 NATtrol™ 1:1,000 7.23E+05 1.00E+07 
 
Table XIX.  Acceptable range of the medium positive control. Using the results of the between-
run precision study, the acceptable range of the medium positive control was calculated.  The 
minimum acceptable concentration was calculated using the following formula: Mean – 
3*(Standard Deviation).  The maximum acceptable concentration was calculated using the 
following formula: Mean + 3*(Standard Deviation).  
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      Controls Influenza and Influenza A-H Subtypes RSV Corona Parainfluenza       
Location Sample Total Events 
Run 
Control 
Internal 
Control 
Influenza 
A H1 H3 H5 
Influenza 
B RSV A RSV B 
Corona 
229E 
Corona 
OC43 
Corona 
SARS 
Corona 
NL63 
Corona 
HKU1 Para 1 Para 2 Para 3 Para 4 Enterovirus/Rhinovirus Metapneumovirus Adenovirus 
1 NTC (dH2O) 2767 36 47 49.5 41 189 44 64 61 53.5 43 59 47 82 36 57.5 51.5 53.5 49 45 64 55 
2 Influenza A H1N1 (2009) 2670 124 1611 8592 37 206 20.5 9 25 56 16 45 56 30 47 45.5 54.5 36 15 34.5 45 38 
3 Influenza A H1N1 (04) 3186 4 1884 7800 5988 44 21 29 30 28 31.5 32.5 46 42 17 19 36 15 37.5 25 20.5 36 
4 Influenza A H3N2 2872 14.5 1750 9443 43 8694 40.5 30.5 15 29.5 23 23 46 36 28 32 28 28.5 40 27.5 30 25.5 
5 Influenza B 2765 41 1648.5 18 14 34 15 2028 28 9 24 27.5 38 9.5 31 28 12.5 5 17 17 44.5 20 
6 RSV A 2845 25 1698 3 0 21 25 38 7848.5 25 4.5 12 17 20 35 31 28 28 8 27 28 26 
7 RSV B 3163 100 1839 22 15 40 0 21 16.5 5610.5 20 4 19 0 26 10 30 21 17 20 15 0 
8 Metapneumovirus 2800 18.5 1584 23 1 28 33.5 5 18 29.5 26.5 4 15 3 0 20.5 15 20.5 18 25 7933.5 0.5 
9 Parainfluenza 1 2526 5.5 2686 2.5 6.5 50 11 11.5 23 11 35 9 9 24 5.5 4094 29 36 24 23.5 32 0 
10 NTC (dH2O) 2823 21 0 8.5 28.5 65 27 18 3 22.5 42 19.5 25 29 23 26.5 19 27 37 51 0 16.5 
11 Parainfluenza 2 2560 24 1208 18 28 63 22 22 30 23 15.5 24 23 20 36 20 6289 37 10 21 0 8 
12 Parainfluenza 3 2809 163.5 2338 28 26.5 36 15.5 25 9 17 7.5 14 17.5 15 20 141.5 21.5 5535 7.5 0.5 19 15 
13 Adenovirus 3 2820 23.5 1571 2.5 9 17 18 27 4.5 43.5 13.5 2 5.5 12 19 38 4 7 26 27 0.5 1656 
14 Enterovirus 2714 16 1669 0 15.5 57.5 24 26.5 0 9.5 14 0 5 0 0 9 3 6 0 5227 24.5 27.5 
15 Rhinovirus 2388 10 1984 0 0 47 13 0 0 14.5 4.5 6 6 0 7 4 0 7.5 4 4019 23.5 0 
16 Coronavirus 229E 2865 0 2011.5 0 0 47 19 0 4 0 6132 2 0 0.5 0 0 2.5 0 21.5 2 0 11 
17 Coronavirus SARS 2709 22 1517 32 21.5 103 18 6 28.5 16 16 18 8068.5 0 3.5 12 47.5 34 5 30 7.5 7.5 
18 Coronavirus OC43 2551 62 1833.5 32 19.5 122 15 33.5 26.5 3 26 3395 69 19 30 26 21 39 14.5 24 0 18 
19 Negative Control 2904 31.5 1978 8 23.5 114 29 34 3.5 22 22.5 18 1.5 16 12 0 20 35 21 24 19 15 
20 Lambda 2871 5724 27 34 26 66 22 0 13.5 42 16 44 25.5 43 35 34 36 23 22.5 16 42 36 
21 NTC (dH2O) 2836 35 18.5 35.5 5 52 42.5 19 41 35.5 52 27.5 39.5 15.5 18 11 28 38 30 8.5 44.5 22 
 
Table XX. Results of the use of the MS2 NATtrol™ molecular control as a full-process internal control in the Luminex xTAG RVP assay, in MFI.  These results are in MFI 
(median fluorescent intensity), and positive results (>300 MFI) are highlighted in orange.  This table is adapted from the output file produced by the Luminex100 Integrated 
System 2.3 software.  
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    Controls Influenza and Influenza A-H Subtypes RSV Corona Parainfluenza       
Location Sample POS Calls Run Control 
Internal 
Control 
Influenza 
A H1 H3 H5 
Influenza 
B 
RSV 
A 
RSV 
B 
Corona 
229E 
Corona 
OC43 
Corona 
SARS 
Corona 
NL63 
Corona 
HKU1 Para 1 Para 2 Para 3 Para 4 
Enterovirus/
Rhinovirus Metapneumovirus Adenovirus 
1 NTC (dH2O) N/A ABS ABS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
2 Influenza A H1N1 (2009) Influenza A ABS PRES POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
3 Influenza A H1N1 (04) Influenza A, H1 ABS PRES POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
4 Influenza A H3N2 Influenza A, H3 ABS PRES POS NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
5 Influenza B Influenza B ABS PRES NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
6 RSV A RSV A ABS PRES NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
7 RSV B RSV B ABS PRES NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
8 Metapneumovirus Metapneumovirus ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG 
9 Parainfluenza 1 Para 1 ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG 
10 NTC (dH2O) N/A ABS ABS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
11 Parainfluenza 2 Para 2 ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG 
12 Parainfluenza 3 Para 3 ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG 
13 Adenovirus 3 Adenovirus ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS 
14 Enterovirus Enterovirus/Rhinovirus ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG 
15 Rhinovirus Enterovirus/Rhinovirus ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG 
16 Coronavirus 229E Corona 229E ABS PRES NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
17 Coronavirus SARS Corona SARS ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG 
18 Coronavirus OC43 Corona OC43 ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
19 Negative Control N/A ABS PRES NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
20 Lambda N/A PRES ABS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
21 NTC (dH2O) N/A ABS ABS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
 
Table XXI.  Results of the use of the MS2 NATtrol™ molecular control as a full-process internal control in the Luminex xTAG RVP assay, in positive calls and negative calls.  
Positive calls, where the target was detected, are highlighted in orange.  This table is adapted from the TDAS RVP-I software’s analysis of the output file produced by the 
Luminex100 Integrated System 2.3 software.  
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Dilution Replicates Mean Cp 
MS2 NATtrol™ Neat (1:5) 24 19.52 
MS2 NATtrol™ 1:10 24 20.70 
MS2 NATtrol™ 1:100 24 24.51 
MS2 NATtrol™ 1:1,000 24 28.84 
MS2 NATtrol™ 1:10,000 24 32.92 
MS2 NATtrol™ 1:50,000 24 35.75 
MS2 NATtrol™ 1:100,000 24 36.74 
MS2 NATtrol™ 1:500,000 24 38.67 
MS2 NATtrol™ 1:1,000,000 24 39.30 
MS2 NATtrol™ 1:5,000,000 21 39.75 
MS2 NATtrol™ 1:10,000,000 13 39.65 
 
Table XXII.  Working range validation study results, with the MS2 NATtrol™ dilutions selected 
for the standard curve calibrators, low positive control, and medium positive control highlighted.  
This table shows the results of the working range validation study, in the form of mean Cp values 
for various MS2 NATtrol™ dilutions that were tested in multiple replicates over a series of runs 
of the MS2 PCR assay.  The MS2 NATtrol™ dilutions that were selected, based on the results of 
this study, to be the standard curve calibrators, low positive control, and medium positive control 
are highlighted in yellow, pink, and green, respectively.  
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Sample Replicates Mean Cp 
MS2 NATtrol™ Neat (1:5) 3 18.96 
MS2 NATtrol™ 1:10 3 21.11 
MS2 NATtrol™ 1:100 3 25.31 
MS2 NATtrol™ 1:1,000 3 29.15 
MS2 NATtrol™ 1:10,000 3 33.25 
MS2 NATtrol™ 1:100,000 3 36.61 
MS2 NATtrol™ 1:500,000 9 39.56 
MS2 NATtrol™ 1:600,000 6 40 
MS2 NATtrol™ 1:800,000 6 40 
MS2 NATtrol™ 1:900,000 6 40 
MS2 NATtrol™ 1:1,000,000 6 40 
MS2 NATtrol™ 1:2,000,000 6 40 
MS2 NATtrol™ 1:3,000,000 6 40 
MS2 NATtrol™ 1:4,000,000 6 40 
MS2 NATtrol™ 1:5,000,000 6 40 
MS2 NATtrol™ 1:6,000,000 6 40 
MS2 NATtrol™ 1:8,000,000 6 40 
MS2 NATtrol™ 1:10,000,000 6 40 
 
Table XXIII.  Limit of detection study results, with the positives and negatives specified in red 
text and blue text, respectively.  This table presents the results of the LOD study, with significant 
positives (Cp ≤ 37) in red and negatives (Cp > 37) in blue.  The criteria for a sample to be 
positive or negative were determined based on the LOD (Cp 37) of the MS2 PCR assay.  A 
sample with a Cp value less than or equal to the LOD (≤ Cp 37) is positive, and a sample with a 
Cp value greater than the LOD (> Cp 37) is negative.  
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Figure 1.  A selection of the MS2 bacteriophage genome, with the target sequences of the 
primers and probe highlighted.  The MS2 bacteriophage genome was obtained from NCBI 
(www.ncbi.nlm.nih.gov), and this selection of the MS2 bacteriophage genome was adapted from 
GenBank (accession number GQ153927.1).  The MS2 Taq forward primer targets the 16bp 
sequence in orange (nucleotides 3169 through 3184).  The MS2 Taq reverse primer targets the 
20bp sequence in blue (nucleotides 3210 through 3229).  The MS2 Taq probe targets the 24bp 
sequence in pink (nucleotides 3186 through 3209).  
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Figure 2.  Map of the 96-well PCR plate for the working range validation study and the real-time stability study.  This figure depicts 
the locations of the various MS2 NATtrol™ dilutions as well as the NTCs (PCR-grade deionized water) on the 96-well PCR plate.  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A NTC 
MS2 NATtrol™ 1:500,000 MS2 NATtrol™ 1:1,000,000 MS2 NATtrol™ 1:5,000,000 
B 
MS2 NATtrol™ low positive 
control (MS2 NATtrol™ 
1:100,000) 
C 
MS2 NATtrol™ medium 
positive control (MS2 
NATtrol™ 1:1,000) 
MS2 NATtrol™ 1:600,000 MS2 NATtrol™ 1:2,000,000 MS2 NATtrol™ 1:6,000,000 
D MS2 NATtrol™ Neat (1:5) Calibrator 
E MS2 NATtrol™ 1:10 Calibrator 
MS2 NATtrol™ 1:800,000 MS2 NATtrol™ 1:3,000,000 MS2 NATtrol™ 1:8,000,000 
F MS2 NATtrol™ 1:100 Calibrator 
G MS2 NATtrol™ 1:10,000 Calibrator 
MS2 NATtrol™ 1:900,000 MS2 NATtrol™ 1:4,000,000 MS2 NATtrol™ 1:10,000,000 
H MS2 NATtrol™ 1:500,000 Calibrator 
 
Figure 3.  Map of the 96-well PCR plate for the limit of detection study.  This figure depicts the locations of the various MS2 
NATtrol™ dilutions as well as the NTCs (PCR-grade deionized water) on the 96-well PCR plate.  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A NTC 
MS2 NATtrol™ Neat (1:5) MS2 NATtrol™ 1:100 MS2 NATtrol™ 1:500,000 
B 
MS2 NATtrol™ low positive 
control (MS2 NATtrol™ 
1:100,000) 
C 
MS2 NATtrol™ medium 
positive control (MS2 
NATtrol™ 1:1,000) 
D MS2 NATtrol™ Neat (1:5) Calibrator 
E MS2 NATtrol™ 1:10 Calibrator 
MS2 NATtrol™ 1:10 MS2 NATtrol™ 1:10,000 Negative Control 
F MS2 NATtrol™ 1:100 Calibrator 
G MS2 NATtrol™ 1:10,000 Calibrator 
H MS2 NATtrol™ 1:500,000 Calibrator 
 
Figure 4.  Map of the 96-well PCR plate for the precision studies and the real-time stability study.  This figure depicts the locations of 
the various MS2 NATtrol™ dilutions as well as the NTCs (PCR-grade deionized water) and negative controls (purified protein 
matrix) on the 96-well PCR plate.  The five MS2 NATtrol™ calibrators were used to produce a standard curve, which was used to 
quantitate the concentrations of the MS2 NATtrol™ low positive control, MS2 NATtrol™ medium positive control, and the other 
MS2 NATtrol™ dilutions run in columns four through twelve.  
 75 
 1 2 3 4 5 6 7 8 9 10 11 12 
A NTC MS2 NATtrol™ Neat (1:5), Time = 0 
MS2 NATtrol™ 1:100, 
Time = 1 
MS2 NATtrol™ 1:500,000, 
Time = 2 
B 
MS2 NATtrol™ low positive 
control (MS2 NATtrol™ 
1:100,000) 
MS2 NATtrol™ 1:10,  
Time = 0 
MS2 NATtrol™ 1:10,000, 
Time = 1 
Negative Control,  
Time = 2 
C 
MS2 NATtrol™ medium 
positive control (MS2 
NATtrol™ 1:1,000) 
MS2 NATtrol™ 1:100, 
Time = 0 
MS2 NATtrol™ 1:500,000, 
Time = 1 
MS2 NATtrol™ Neat (1:5), 
Time = 3 
D MS2 NATtrol™ Neat (1:5) Calibrator 
MS2 NATtrol™ 1:10,000, 
Time = 0 
Negative Control,  
Time = 1 
MS2 NATtrol™ 1:10,  
Time = 3 
E MS2 NATtrol™ 1:10 Calibrator MS2 NATtrol™ 1:500,000, Time = 0 
MS2 NATtrol™ Neat (1:5), 
Time = 2 
MS2 NATtrol™ 1:100, 
Time = 3 
F MS2 NATtrol™ 1:100 Calibrator 
Negative Control,  
Time = 0 
MS2 NATtrol™ 1:10,  
Time = 2 
MS2 NATtrol™ 1:10,000, 
Time = 3 
G MS2 NATtrol™ 1:10,000 Calibrator 
MS2 NATtrol™ Neat (1:5), 
Time = 1  
MS2 NATtrol™ 1:100, 
Time = 2 
MS2 NATtrol™ 1:500,000, 
Time = 3 
H MS2 NATtrol™ 1:500,000 Calibrator 
MS2 NATtrol™ 1:10,  
Time = 1  
MS2 NATtrol™ 1:10,000, 
Time = 2 
Negative Control,  
Time = 3 
 
Figure 5.  Map of the 96-well PCR plate for the freeze-thaw (transport) stability study.  This figure depicts the locations of the various 
MS2 NATtrol™ dilutions as well as the NTCs (PCR-grade deionized water) and negative controls (purified protein matrix) on the 96-
well PCR plate.  The samples described by a time underwent that number of freeze-thaw cycles, in which they were frozen at -80ºC 
and thawed at room temperature.  The standard curve calibrators, low positive control, and medium positive control did not undergo 
any freeze-thaw cycles.   
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 1 2 3 4 5 6 7 8 9 10 11 12 
A NTC MS2 NATtrol™ Neat (1:5), Time = 1 
MS2 NATtrol™ 1:100, 
Time = 2 
MS2 NATtrol™ 1:500,000, 
Time = 3 
B 
MS2 NATtrol™ low positive 
control (MS2 NATtrol™ 
1:100,000) 
MS2 NATtrol™ 1:10,  
Time = 1 
MS2 NATtrol™ 1:10,000, 
Time = 2 
Negative Control,  
Time = 3 
C 
MS2 NATtrol™ medium 
positive control (MS2 
NATtrol™ 1:1,000) 
MS2 NATtrol™ 1:100, 
Time = 1 
MS2 NATtrol™ 1:500,000, 
Time = 2 
MS2 NATtrol™ Neat (1:5), 
Time = 4 
D MS2 NATtrol™ Neat (1:5) Calibrator 
MS2 NATtrol™ 1:10,000, 
Time = 1 
Negative Control,  
Time = 2 
MS2 NATtrol™ 1:10,  
Time = 4 
E MS2 NATtrol™ 1:10 Calibrator MS2 NATtrol™ 1:500,000, Time = 1 
MS2 NATtrol™ Neat (1:5), 
Time = 3 
MS2 NATtrol™ 1:100, 
Time = 4 
F MS2 NATtrol™ 1:100 Calibrator 
Negative Control,  
Time = 1 
MS2 NATtrol™ 1:10,  
Time = 3 
MS2 NATtrol™ 1:10,000, 
Time = 4 
G MS2 NATtrol™ 1:10,000 Calibrator 
MS2 NATtrol™ Neat (1:5), 
Time = 2 
MS2 NATtrol™ 1:100, 
Time = 3 
MS2 NATtrol™ 1:500,000, 
Time = 4 
H MS2 NATtrol™ 1:500,000 Calibrator 
MS2 NATtrol™ 1:10,  
Time = 2 
MS2 NATtrol™ 1:10,000, 
Time = 3 
Negative Control,  
Time = 4 
 
Figure 6.  Map of the 96-well PCR plate for the open-vial (use-life) stability study.  This figure depicts the locations of the various 
MS2 NATtrol™ dilutions as well as the NTCs (PCR-grade deionized water) and negative controls (purified protein matrix) on the 96-
well PCR plate.  The time represents that the sample to be extracted came from the first, second, third, or fourth use of the same vial of 
a particular dilution of MS2 NATtrol™.  The standard curve calibrators, low positive control, and medium positive control samples to 
be extracted came from single-use vials of the appropriate MS2 NATtrol™ dilutions.
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Figure 7.  Working range validation study amplification curves.  The amplification curves 
presented here are representative of the amplification curves generated by the LightCycler® 480 
Software in the working range validation study.  The graph plots Fluorescence vs. Cycles.  
Amplification curves in red correspond to samples that the LightCycler® 480 Software called 
positive, and amplification curves in green correspond to samples that the LightCycler® 480 
Software called negative.  
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Figure 8.  Representative amplification curves of the standard curve calibrators.  These 
amplification curves of the standard curve calibrators were generated in the precision studies by 
the LightCycler® Software.  The amplification curves corresponding to the replicates of the MS2 
NATtrol™ neat (1:5) dilution, MS2 NATtrol™ 1:10 dilution, MS2 NATtrol™ 1:100 dilution, 
MS2 NATtrol™ 1:10,000 dilution, and MS2 NATtrol™ 1:500,00 dilution are in maroon, aqua, 
yellow-green, blue, and bright red, respectively.  
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Figure 9.  Representative amplification curves of the low and medium positive controls.  These 
amplification curves of the low and medium positive controls were generated in the precision 
studies by the LightCycler® 480 Software.  The amplification curves corresponding to the 
replicates of the medium positive control (MS2 NATtrol™ dilution 1:1,000) are in yellow.  The 
amplification curves corresponding to the replicates of the low positive control (MS2 NATtrol™ 
1:100,000 dilution) are in gray.  
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Standard Curve 
Calibrator 
Dilution 
(Decimal) Mean Cp 
Standard 
Deviation 
Minimum 
Acceptable 
Cp 
Maximum 
Acceptable 
Cp 
MS2 NATtrol™ 1:500,000 0.000002 38.13 1.38 33.99 42.27 
MS2 NATtrol™ 1:10,000 0.0001 33.22 0.75 30.97 35.47 
MS2 NATtrol™ 1:100 0.01 25.43 0.28 24.59 26.27 
MS2 NATtrol™ 1:10 0.1 21.19 0.30 20.29 22.09 
MS2 NATtrol™ Neat (1:5) 0.2 19.47 0.64 17.55 21.39 
 
Figure 10.  Acceptable ranges of the standard curve calibrators, plotted as Mean Cp vs. MS2 
NATtrol™ Dilution.  To plot the dilutions of the standard curve calibrators on the graph, they 
were converted to decimals.  These decimals are listed in the table, along with the mean Cp, 
minimum acceptable Cp, and maximum acceptable Cp for each standard curve calibrator.  The 
points on the graph represent the mean Cp of each standard curve calibrator, and the bars at each 
point on the graph represent the acceptable range of each standard curve calibrator, with the 
bottom bar being the minimum acceptable Cp and the top bar being the maximum acceptable Cp.  
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Date of Run Time (Days) Mean Cp Standard Deviation Cp 
11/13/2013 0 19.29 0.17 
11/20/2013 7 19.66 0.16 
11/22/2013 9 19.61 0.14 
02/21/2014 100 19.38 0.32 
02/28/2014 107 20.10 1.01 
03/04/2014 111 19.15 0.07 
 
Figure 11.  Results of the real-time stability study for the MS2 NATtrol™ Neat (1:5) stock 
material, plotted as Mean Cp vs. Time (Days).  The table lists the points plotted on this graph as 
well as the standard deviation for each point, which is represented for each point on the graph by 
standard deviation bars.  For the purpose of this real-time stability study, the time, measured in 
days, started on the date of the first run of this study.  
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Date of Run Time (Days) Mean Cp Standard Deviation Cp 
11/13/2013 0 20.56 0.14 
11/20/2013 7 20.81 0.17 
11/22/2013 9 20.75 0.16 
02/21/2014 100 21.28 0.38 
02/28/2014 107 20.94 0.26 
03/04/2014 111 21.22 0.26 
 
Figure 12.  Results of the real-time stability study for the MS2 NATtrol™ 1:10 dilution, plotted 
as Mean Cp vs. Time (Days).  The table lists the points plotted on this graph as well as the 
standard deviation for each point, which is represented for each point on the graph by standard 
deviation bars.  For the purpose of this real-time stability study, the time, measured in days, 
started on the date of the first run of this study.  
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Date of Run Time (Days) Mean Cp Standard Deviation Cp 
11/13/2013 0 24.10 0.11 
11/20/2013 7 24.62 0.21 
11/22/2013 9 24.79 0.19 
02/21/2014 100 25.23 0.31 
02/28/2014 107 25.67 0.16 
03/04/2014 111 25.58 0.13 
 
Figure 13.  Results of the real-time stability study for the MS2 NATtrol™ 1:100 dilution, plotted 
as Mean Cp vs. Time (Days).  The table lists the points plotted on this graph as well as the 
standard deviation for each point, which is represented for each point on the graph by standard 
deviation bars.  For the purpose of this real-time stability study, the time, measured in days, 
started on the date of the first run of this study.  
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Date of Run Time (Days) Mean Cp Standard Deviation Cp 
11/13/2013 0 32.01 0.11 
11/20/2013 7 32.87 0.20 
11/22/2013 9 33.88 0.13 
02/21/2014 100 32.25 0.39 
02/28/2014 107 33.57 0.27 
03/04/2014 111 33.03 0.29 
 
Figure 14.  Results of the real-time stability study for the MS2 NATtrol™ 1:10,000 dilution, 
plotted as Mean Cp vs. Time (Days).  The table lists the points plotted on this graph as well as 
the standard deviation for each point, which is represented for each point on the graph by 
standard deviation bars.  For the purpose of this real-time stability study, the time, measured in 
days, started on the date of the first run of this study.  
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Date of Run Time (Days) Mean Cp Standard Deviation Cp 
11/13/2013 0 37.63 0.19 
11/20/2013 7 38.38 0.65 
11/22/2013 9 40 0 
02/21/2014 100 36.03 0.69 
02/28/2014 107 38.62 0.48 
03/04/2014 111 38.50 0.53 
 
Figure 15.  Results of the real-time stability study for the MS2 NATtrol™ 1:500,000 dilution, 
plotted as Mean Cp vs. Time (Days).  The table lists the points plotted on this graph as well as 
the standard deviation for each point, which is represented for each point on the graph by 
standard deviation bars.  For the purpose of this real-time stability study, the time, measured in 
days, started on the date of the first run of this study.  
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Number of Freeze-Thaw Cycles Mean Cp Standard Deviation Cp 
0 18.39 0.11 
1 19.36 0.15 
2 20.07 0.09 
3 20.06 0.11 
 
Figure 16.  Results of the freeze-thaw (transport) stability study for the MS2 NATtrol™ Neat 
(1:5) stock material, plotted as Mean Cp vs. Number of Freeze-Thaw Cycles.  Here, number of 
freeze-thaw cycles refers to the number of freeze-thaw cycles, in which the sample is frozen at -
80ºC and thawed at room temperature, that the sample underwent prior to being extracted.  The 
table lists the points plotted on the graph as well as the standard deviation for each point, which 
is represented for each point on the graph by standard deviation bars.   
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Number of Freeze-Thaw Cycles Mean Cp Standard Deviation Cp 
0 20.52 0.24 
1 20.87 0.05 
2 21.88 0.05 
3 22.38 0.17 
 
Figure 17.  Results of the freeze-thaw (transport) stability study for the MS2 NATtrol™ 1:10 
dilution, plotted as Mean Cp vs. Number of Freeze-Thaw Cycles.  Here, number of freeze-thaw 
cycles refers to the number of freeze-thaw cycles, in which the sample is frozen at -80ºC and 
thawed at room temperature, that the sample underwent prior to being extracted.  The table lists 
the points plotted on the graph as well as the standard deviation for each point, which is 
represented for each point on the graph by standard deviation bars.    
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Number of Freeze-Thaw Cycles Mean Cp Standard Deviation Cp 
0 24.82 0.06 
1 24.96 0.03 
2 25.74 0.05 
3 26.20 0.10 
 
Figure 18.  Results of the freeze-thaw (transport) stability study for the MS2 NATtrol™ 1:100 
dilution, plotted as Mean Cp vs. Number of Freeze-Thaw Cycles.  Here, number of freeze-thaw 
cycles refers to the number of freeze-thaw cycles, in which the sample is frozen at -80ºC and 
thawed at room temperature, that the sample underwent prior to being extracted.  The table lists 
the points plotted on the graph as well as the standard deviation for each point, which is 
represented for each point on the graph by standard deviation bars.   
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Number of Freeze-Thaw Cycles Mean Cp Standard Deviation Cp 
0 33.04 0.15 
1 33.10 0.00 
2 33.61 0.38 
3 33.58 0.05 
 
Figure 19.  Results of the freeze-thaw (transport) stability study for the MS2 NATtrol™ 1:10,000 
dilution, plotted as Mean Cp vs. Number of Freeze-Thaw Cycles.  Here, number of freeze-thaw 
cycles refers to the number of freeze-thaw cycles, in which the sample is frozen at -80ºC and 
thawed at room temperature, that the sample underwent prior to being extracted.  The table lists 
the points plotted on the graph as well as the standard deviation for each point, which is 
represented for each point on the graph by standard deviation bars.   
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Number of Freeze-Thaw Cycles Mean Cp Standard Deviation Cp 
0 39.29 0.75 
1 39.33 0.60 
2 38.55 0.49 
3 38.46 0.86 
 
Figure 20.  Results of the freeze-thaw (transport) stability study for the MS2 NATtrol™ 
1:500,000 dilution, plotted as Mean Cp vs. Number of Freeze-Thaw Cycles.  Here, number of 
freeze-thaw cycles refers to the number of freeze-thaw cycles, in which the sample is frozen at -
80ºC and thawed at room temperature, that the sample underwent prior to being extracted.  The 
table lists the points plotted on the graph as well as the standard deviation for each point, which 
is represented for each point on the graph by standard deviation bars.   
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Vial Usage Mean Cp Standard Deviation Cp 
1 21.78 2.26 
2 19.69 0.20 
3 19.59 0.06 
4 20.24 0.57 
 
Figure 21.  Results of the open-vial (use-life) stability study for the MS2 NATtrol™ Neat (1:5) 
stock material, plotted as Mean Cp vs. Vial Usage.  Here, vial usage refers to the sample to be 
extracted coming from the first, second, third, or fourth use of the same vial of MS2 NATtrol™ 
Neat (1:5) stock material.  The table lists the points plotted on the graph as well as the standard 
deviation for each point, which is represented for each point on the graph by standard deviation 
bars.  
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Vial Usage Mean Cp Standard Deviation Cp 
1 21.53 0.14 
2 21.56 0.18 
3 22.11 0.42 
4 21.84 0.15 
 
Figure 22.  Results of the open-vial (use-life) stability study for the MS2 NATtrol™ 1:10 
dilution, plotted as Mean Cp vs. Vial Usage.  Here, vial usage refers to the sample to be extracted 
coming from the first, second, third, or fourth use of the same vial of MS2 NATtrol™ 1:10 
dilution.  The table lists the points plotted on the graph as well as the standard deviation for each 
point, which is represented for each point on the graph by standard deviation bars.  
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Vial Usage Mean Cp Standard Deviation Cp 
1 26.51 0.58 
2 27.11 0.41 
3 26.13 0.12 
4 27.16 1.11 
 
Figure 23.  Results of the open-vial (use-life) stability study for the MS2 NATtrol™ 1:100 
dilution, plotted as Mean Cp vs. Vial Usage.  Here, vial usage refers to the sample to be extracted 
coming from the first, second, third, or fourth use of the same vial of MS2 NATtrol™ 1:100 
dilution.  The table lists the points plotted on the graph as well as the standard deviation for each 
point, which is represented for each point on the graph by standard deviation bars.  
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Vial Usage Mean Cp Standard Deviation Cp 
1 34.96 0.59 
2 35.23 0.75 
3 35.25 0.67 
4 35.51 1.08 
 
Figure 24.  Results of the open-vial (use-life) stability study for the MS2 NATtrol™ 1:10,000 
dilution, plotted as Mean Cp vs. Vial Usage.  Here, vial usage refers to the sample to be extracted 
coming from the first, second, third, or fourth use of the same vial of MS2 NATtrol™ 1:10,000 
dilution.  The table lists the points plotted on the graph as well as the standard deviation for each 
point, which is represented for each point on the graph by standard deviation bars.  
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Vial Usage Mean Cp Standard Deviation Cp 
1 40 0 
2 40 0 
3 40 0 
4 40 0 
 
Figure 25.  Results of the open-vial (use-life) stability study for the MS2 NATtrol™ 1:500,000 
dilution, plotted as Mean Cp vs. Vial Usage.  Here, vial usage refers to the sample to be extracted 
coming from the first, second, third, or fourth use of the same vial of MS2 NATtrol™ 1:500,000 
dilution.  The table lists the points plotted on the graph as well as the standard deviation for each 
point, which is represented for each point on the graph by standard deviation bars.  
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Dilution Mean Cp Dilution (Decimal) 
MS2 NATtrol™ Neat (1:5) 18.96 0.2 
MS2 NATtrol™ 1:10 21.11 0.1 
MS2 NATtrol™ 1:100 25.31 0.01 
MS2 NATtrol™ 1:1,000 29.15 0.001 
MS2 NATtrol™ 1:10,000 33.25 0.0001 
MS2 NATtrol™ 1:100,000 36.61 0.00001 
MS2 NATtrol™ 1:500,000 39.56 0.000002 
MS2 NATtrol™ 1:600,000 40 0.00000166667 
MS2 NATtrol™ 1:800,000 40 0.00000125 
MS2 NATtrol™ 1:900,000 40 0.00000111111 
MS2 NATtrol™ 1:1,000,000 40 0.000001 
MS2 NATtrol™ 1:2,000,000 40 0.0000005 
MS2 NATtrol™ 1:3,000,000 40 0.000000333333 
MS2 NATtrol™ 1:4,000,000 40 0.00000025 
MS2 NATtrol™ 1:5,000,000 40 0.0000002 
MS2 NATtrol™ 1:6,000,000 40 0.000000166667 
MS2 NATtrol™ 1:8,000,000 40 0.000000125 
MS2 NATtrol™ 1:10,000,000 40 0.0000001 
 
Figure 26.  Results of the limit of detection study, plotted as MS2 NATtrol™ Dilution vs. Mean 
Cp.  To plot the MS2 NATtrol™ dilutions on the graph, they were converted to decimals.  The 
table lists the points on the graph, including these decimals.  Figure 27 presents a zoomed in 
view of a selection of the graph presented here.  The zoomed in view is required to assess where 
the curve begins to flatten, in order to determine the limit of detection of the assay.  
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Dilution Mean Cp Dilution (Decimal) 
MS2 NATtrol™ 1:1,000 29.15 0.001 
MS2 NATtrol™ 1:10,000 33.25 0.0001 
MS2 NATtrol™ 1:100,000 36.61 0.00001 
MS2 NATtrol™ 1:500,000 39.56 0.000002 
MS2 NATtrol™ 1:600,000 40 0.00000166667 
MS2 NATtrol™ 1:800,000 40 0.00000125 
MS2 NATtrol™ 1:900,000 40 0.00000111111 
MS2 NATtrol™ 1:1,000,000 40 0.000001 
MS2 NATtrol™ 1:2,000,000 40 0.0000005 
MS2 NATtrol™ 1:3,000,000 40 0.000000333333 
MS2 NATtrol™ 1:4,000,000 40 0.00000025 
MS2 NATtrol™ 1:5,000,000 40 0.0000002 
MS2 NATtrol™ 1:6,000,000 40 0.000000166667 
MS2 NATtrol™ 1:8,000,000 40 0.000000125 
MS2 NATtrol™ 1:10,000,000 40 0.0000001 
 
Figure 27.  A selection of the results of the limit of detection study, plotted as MS2 NATtrol™ 
Dilution vs. Mean Cp.  This graph is a zoomed in view of a selection of Figure 26.  The table 
lists the selection of points that are included on this graph.  From this zoomed in view, it is 
evident that the curve begins to flatten around a Cp value of 37.  Therefore, the limit of detection 
of this assay is at Cp 37.   
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